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Abstract
There is inadequate information on the fetal safety of drugs during
pregnancy for the majority of marketed drugs. It is challenging to examine
the safety and efficacy of drugs during pregnancy due to the ethical issues of
exposing unborn babies to these chemicals. It often takes many years before
associations between a drug and its safety, efficacy, and toxicity in
pregnancy can be established. This thesis will examine strategies in signal
detection of the effects of drug exposures during pregnancy.
Meta-analyses have become useful in the area of clinical teratology.
Observational studies provide the main source of information in these metaanalyses. Although the quality of meta-analysis of small observational
studies is challenging, it is an effective strategy, as shown in the present
study, in predicting correct signals to estimate teratogenicity years before
large cohort studies become available.
Results of retrospective pregnancy registries are commonly reported
in regulatory documentations. However, little data are available on the
precision of the estimates from such registries. The present study confirms a
consistent bias against the null hypothesis in a retrospective registry which
needs to be considered when interpreting such data as a strategy in
generating safety/risk signals of new drugs.
H1 antihistamines are used for the treatment of nausea and vomiting
during pregnancy as well as the symptomatic relief of allergy. Although they
are felt to be safe, several studies have challenged this assumption. By using
i

meta-analysis, the safety of antihistamines has been confirmed in this thesis
with over 1.3 million exposed and control subjects.
Typically, after experimental animal studies, novel therapeutic
modalities are tested by randomized controlled trials. Cumulative metaanalysis is an effective strategy to detect a possible time- dependent effect
and potential bias against the null hypothesis, whether antioxidant treatment
decreases the rates of preeclampsia. I have shown that the initial favorable
effect seen in the first studies is nullified as the sample sizes and number of
studies is increased.
There is a need to continue using and developing the above strategies
to study the safety and efficacy of drugs to improve maternal fetal health.
Keywords
Meta-analysis, Pregnancy outcomes, Retrospective pregnancy registries, H1
antihistamine, Cumulative meta-analysis.
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Chapter 1: General introduction.
Presently, it often takes many years before any association is established
between a drug and its toxicity, safety, and/or efficacy in pregnancy are
established. With 50% of all pregnancies being unplanned [1], large numbers of
women are exposed inadvertently to medications in early pregnancy. In addition,
many pregnant women suffer from conditions that require continued treatment
during pregnancy [2]; therefore, there is a need to be able to identify fetal risks as
soon as possible. This ‘integrated articles’ thesis is based on five articles I have
published over the last four years, all focusing on signal detection of the effects of
exposures during pregnancy.
1.1. Understanding the role of meta-analysis in maternal-fetal health research.
Usually, randomized controlled drug studies cannot include pregnant women
due to ethical issues surrounding the fear of potential teratogenic risk given the
unknown safety profile of the new drugs. Therefore, prenatal adverse drug effect
data are rarely known from such sources. Some pregnant women may be exposed
to a new drug in the premarketing phase unintentionally; hence data are often
collected in retrospective or prospective observations. Thus, post marketing
epidemiological studies based on observational data are the main methods by
which to study potential teratogenic effects when randomization is impossible [3].
However, over the past two decades, systematic reviews and meta-analyses
of observational studies have been increasingly utilized in the field of clinical
teratology as part of the general trend of a 500-fold increase in publications [4]. A
systematic review is defined as “the application of scientific strategies that limit
bias by a systematic assembly, critical appraisal, and synthesis of all relevant
studies on a specific topic” [5]. In clinical teratology, the specific topic is typically
the risks of major congenital malformations, miscarriage, or prematurity in the
1
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exposed versus non-exposed groups, or the long term neurodevelopmental effects
of in-utero exposure [6]. Meta-analysis is defined as the statistical synthesis of
results from several independent, but ‘combinable’ studies, leading to a
quantitative summary of the pooled results [5].
In the hierarchy of studies, meta-analyses and systematic reviews of
randomized studies are ranked at the highest level of evidence. In contrast,
systematic reviews and meta-analyses of observational studies possess more
weaknesses and potential biases. Reporting of observational research is often not
detailed and clear enough to assess the strengths and weaknesses of the
investigations [7]. Furthermore, multiple deficiencies, such as heterogeneity [8],
methodological quality [9], deficiencies in statistical methods [10], and controlling
for all potential sources of bias [11], have been widely reported. As a result, the
quality of published meta-analyses of observational studies ranges widely and the
conclusions reached from the same set of studies may be conflicting.
Typically, after a new drug is introduced into the market, case reports, case
series, and small, underpowered controlled cohort studies begin to emerge.
Synthesizing these small studies in meta-analyses allows for an increase in sample
size and, hence in the power to distinguish relatively small teratological signals.
Only much later, when the drug has been used on a large scale, are large cohort
studies published, and they are sufficiently powered to draw more solid
conclusions on fetal safety/ risks.
There is a need to study and examine the validity of the conclusions reached
by meta-analyses of small observational teratology studies as compared with the
newer, very large studies. As meta-analyses of small observational studies are
available years before large, appropriately powered cohort studies become
2

available, they may be important to consider in clinical counseling. It is therefore
logical to try to estimate how early a valid signal (positive or negative) can be
generated from meta-analyses before the large cohort studies are published
(Chapter 3).
1.2. Understanding the role of retrospective pregnancy exposure registries in
maternal-fetal health research.
Another important strategy to assess drug safety during pregnancy,
employed mostly by drug companies, is using pregnancy exposure registries.
Prospective pregnancy exposure registries, where pregnant women are enrolled
before the outcomes of their pregnancies are known, are recognized as an
important method for ascertaining risks associated with a drug exposure during
pregnancy. In contrast, retrospective pregnancy exposure registries are based on
women/physicians contacting the registry after pregnancy outcomes are known.
Retrospective registries have been regarded as the weakest type of teratogenic
evidence and were never viewed by clinicians and scientists as data that can lead to
quantitative estimates of risk/safety. However, is this viewpoint justified?
There is a reporting bias that makes interpretation of retrospective pregnancy
exposure registries challenging [12]. Until now, this type of bias has led clinicians,
scientists and regulatory bodies to discard such data. But if the bias leads to a
stable increase in signal, it may also mean that, if the retrospective study does not
show malformation rates above the expected baseline of 3-5%, the drug is probably
not associated with an increased teratogenic risk. Since most medicinal drugs are
not teratogenic [13], the ability to use such data may empower women and their
health professionals to use much needed drugs years before large prospective
studies are conducted.
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There is a need to compare the rates of reported malformations in
retrospective pregnancy exposure registries vs. prospective pregnancy exposure of
the same kind of drug at the same period of time via the same drug company in an
effort to make the retrospective registries more useable and more a part of the
overall analysis of teratogenicity (Chapter 4).
1.3. Applying meta-analysis to address unresolved research question in
teratology with H1 antihistamine as an example.
H1 antihistamine is classified as either the first or old generation H1
antihistamine such as hydroxyzine or as the second or new generation H1
antihistamine such as cetirizine. The first generation class of H1 antihistamine has
the ability to cross the blood brain barrier which can be considered a disadvantage
when we want to treat allergy because it will cause a sedative side effect. However
crossing the blood brain barrier can be an advantage when we want to treat nausea
and vomiting during pregnancy (NVP). The second generation class of H1
antihistamine has less ability to cross the blood brain barrier which gives this class
a big advantage when we want to treat allergy or asthma without the sedative side
effect [14].
The best approach to quantify the safety/risk of H1 antihistamine during
pregnancy is to conduct a meta-analysis of all available observational control
studies and this is what Seto and his colleagues did twenty years ago and they
concluded that H1 antihistamine can be safely used during pregnancy [15].
Another research group re-analyzed the Seto meta-analysis without adding new
research and they found contradictory results [16]. Therefore, there is a need to
conduct more observational studies on H1 antihistamines and also conduct a new
meta-analysis on all available studies on H1 antihistamines to assess the risk of
malformation and other pregnancy outcomes. We focused on assessing the safety
4

of using cetirizine and its prodrug hydroxyzine during the first trimester by
conducting meta-analyses of the current and all available cohort studies that
studied adverse pregnancy outcomes.
The current meta-analyses focus primarily on first trimester exposure. This
was accomplished by including studies where the first trimester exposure to H1
antihistamines was necessary. Studies where mothers were also exposed in
subsequent trimesters were included but this was not a requirement. The reasons
for focusing on the first trimester exposure are twofold. First of all, the first
trimester is a critical time for fetal development and thus an extremely important
period for assessing the potential adverse effects of drugs. Gross structural
abnormalities, which can be readily apparent in newborns, occur following
exposure to teratogenic agents during this stage of organogenesis, when tissues and
organs are developing [17]. As a result, most studies assessing the effects of drug
exposure during pregnancy typically look at the first trimester exposure or view
this timing of exposure as important.
Presently there is sufficient research to power a safety analysis given the
large number of studies focusing on first trimester exposure. This can be partly
caused by the commonplace use of H1 antihistamines during the first trimester. A
woman may be given H1 antihistamines intentionally to treat NVP or another
condition that presents during the first trimester. Alternatively, with 50% of
pregnancies being unplanned [1], a woman may take prescribed or over the counter
H1 antihistamines for treatment of a medical condition while being unaware of her
pregnancy. Therefore, it is necessary to adequately and accurately assess the risks
associated with H1 antihistamine use through meta-analysis (Chapter 5 and
Chapter 6).
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1.4. Cumulative meta-analysis as a tool in detecting the emergence of evidence
in teratology, treatment of preeclampsia as an example.
Meta-analysis in general is not a statistical method that simply combines
results from different studies and aggregates them as a large study. In metaanalysis, studies that include larger sample sizes and a lesser degree of variabilities
are weighted more than other smaller studies. In meta-analysis there are two
models, fixed effect and random effect. Fixed effect model is usually used when
the studies come from the same research group and are highly homogenous. On the
other hand, the random effect model is used when the studies come from different
research groups. The big difference between the two models is the weighting of the
studies. Studies with a smaller sample size have more weight (credit) in the
random effect model estimate than on the fixed effect model estimate [18].
The forest plot is the results figure of a typical meta-analysis. This figure
shows the effect measure of each study (like risk ratio or odds ratio) as well as its
confidence interval and the weighted level. Also, the forest plot shows the
summary of the overall effect measure and its confidence interval.
In case of cumulative meta-analysis, the result of the studies are
accumulated from the earliest to the latest, in a way that each new study includes a
synthesis of all prior studies. This sequential combining of the studies’ results has
an advantage of viewing whether there is consistency in the results of consecutive
studies or if there is change in the direction of the overall estimate when more
recent studies are added [18].
Taking the advantage of cumulative meta-analysis, the researcher can use it
as a tool in detecting the emergence of evidence especially after a new remedy for
pregnancy complications enters the market. Conducting cumulative meta-analysis
6

to examine changes over time in the pooled effect size of randomized control trials
published on the protective effects of antioxidants and low dose aspirin against
preeclampsia is used in this thesis to predict the potential bias against the null
hypothesis (Chapter 7).
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Chapter 2: Objectives and hypotheses.
2.1. Objectives.
1) To systematically review the literature to examine the validity of the
conclusions reached by meta-analyses of small observational studies by comparing
the

results

reached

in

these

meta-analyses

with

more

recent,

large,

methodologically superior studies published on the same topic at a later date.
2) To compare the rates of major congenital malformations reported in
retrospective versus prospective registries of the same drug to quantify the
potential bias of retrospective reports.
3) To systematically review the literature to conduct meta-analyses to
measure the rate of adverse pregnancy outcomes of cetirizine and all H1antihistamines after the first trimester exposure.
4) To conduct cumulative meta-analyses to examine changes over time in
the pooled effect size of randomized control trials published on the protective
effects of antioxidants and low dose aspirin against preeclampsia, and to identify
determinants that may affect such changes.
2.2. Hypotheses.
1) The direction of the conclusions reached by meta-analyses of small
studies on several teratology topics are similar to the results reached by more
recent, large, methodologically superior studies published on the same topic at a
later date.
2) There is a systematic bias of retrospective registries when the rates of
major congenital malformations reported in retrospective registries are much
higher than prospective registries of the same drug, which also suggests that if the
9

retrospective registries did not show increase in major congenital malformations
above the baseline risk, the drug is probably not a major teratogen.
3) The use of cetirizine and all H1-antihistamines during the first trimester is
not associated with an increased risk of adverse pregnancy outcomes.
4) Cumulative meta-analysis is an effective tool in predicting potential bias
against the null hypothesis of randomized control trials published on the protective
effects of antioxidants and low dose aspirin against preeclampsia.
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Chapter 3: The role of meta-analyses in identifying human teratogenicity.
This chapter has been published previously as part of a book chapter.
Etwel F, Hutson JR, Madadi P, Gareri J, Koren G. Fetal and perinatal exposure to
drugs and chemicals: novel biomarkers of risk. Annu Rev Pharmacol Toxicol.
2014; 54:295-315.
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3.1. Introduction.
Typically, randomized controlled drug studies exclude pregnant women
owing to fear of teratogenic risk. As a result, prenatal adverse drug effects data are
rarely available from randomized trials, and epidemiological studies based on
observational data constitute the main data source [1].
Reporting of observational research is often not sufficiently detailed and
clear to assess the potential strengths and weaknesses of these investigations.
Multiple deficiencies such as heterogeneity, methodological quality, insufficient
statistical methods, and control of potential sources of bias have been widely
recognized [2, 3].
Typically, after many years during which small cohort studies report on fetal
safety/risk of a particular drug, administrative databases may report on large
numbers of patients exposed to that agent. Although the strength of these studies
lies in their large size, these large cohort studies take many years to conduct and
are published long after the small cohort studies are published. The synthesis of
these small cohort studies into a systematic review and meta-analysis may yield an
important early signal for the safety/risk of drug use in pregnancy.
Over the past two decades, such systematic reviews and meta-analyses of
observational studies have been increasingly published in the field of clinical
teratology [4]. To date, the conclusions reached by meta-analyses of small
observational teratological studies have not been validated through comparison
with those reached by more recent, very large cohort studies.
3.2. Methods.
As the first step in validating such conclusions, we identified all metaanalyses of small observational teratological studies published in peer review
12

journals. Meta-analyses were eligible for consideration if the outcome measures
were the risk of congenital malformation and/or the risk of long-term
neurodevelopment of children after in utero exposure to therapeutic drugs in the
first trimester of pregnancy.
As the second step, we identified subsequently published large teratological
cohort studies on the same drug addressing the same endpoint. Large cohort studies
were judged suitable for inclusion in this review if the number of women exposed
to the drug in question exceeded either 1,000 or the combined number of total
cases in the corresponding meta-analysis.
3.3. Results.
Of more than 60 meta-analyses on medicinal drugs published by December
31, 2012, 9 meta-analyses could be matched to large, later cohort studies on the
same drug (Table 3). There were 7 “negative” meta-analyses (i.e., showing no
teratological effects) and 2 “positive” ones (showing either morphological or
developmental adverse effects). In all 9 instances, the meta-analyses accurately
predicted the results of the later, large cohort studies. The AMSTAR scores were in
the medium range in all 9 meta-analyses, and the MINORS quality score of the
large cohort studies was 17.9 ± 1.4 (mean ± standard deviation), which is
considered to be on the border of “good” quality (Appendix 2: Detailed
characteristics of the included studies).
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Table 3. Characteristics of the nine meta-analyses included in the comparison
with large cohort studies
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Type of exposure
and outcome

MA
reference

Association
measure
(95% CI)

Large
study
reference

Association measure
(95% CI)

Benzodiazepines and
MM

[7]

OR = 0.90 (0.611.35)

[8]

OR = 1.12 (0.91-1.36)

Untreated epilepsy
and MM

[9]

OR = 1.92 (0.924.00)

[10]

OR = 1.00 (0.8-1.4)

Proton-pump
inhibitors and MM

[11]

RR = 1.18 (0.721.94)

[12]

OR = 1.10 (0.91-1.34)

H2 blockers and
MM

[13]

OR = 0.99 (0.601.65)

[14]

OR = 1.14 (0.89-1.45)

ACE inhibitors and
MM

[15]

OR = 1.41 (0.663.04)

[16]

OR = 1.12 (0.83-1.49)

Valproic acid and
MM

[17]

RR = 3.77 (2.18 6.52)

[18]

(Spina bifida)
RR = 12.7 (7.7-20.7)

Valproic acid and
reduction in IQ

[19]

P = 0.001

[20]

P = 0.009

Carbamazepine and
reduction in IQ

[19]

P = 0.39

[20]

P = 0.20

Varicella infection
and MM

[21]

Risk = 2.2 %
(0-4.6%)

[22]

Risk = 0.4%
(0.05-1.5%)

CI: Confidence Interval, MA: Meta-Analysis, MM: Major Malformations, OR: Odds Ratio,
RR: Relative Risk.
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3.4. Discussion.
It is encouraging that meta-analyses of earlier, albeit smaller, cohort studies
tend to generate an accurate overall teratogenic signal in estimating human
teratogenicity years before large and methodologically superior cohort studies are
published. The meta-analyses offer clinicians, scientists, and regulators an earlier
signal for the presence or lack of teratogenic risk and hence can have an important
impact on clinical practice.
3.5. Conclusion.
Meta-analyses of small cohort studies of pregnancy outcome appropriately
predict results of large cohort studies.
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Chapter 4: Bias against the null hypothesis in retrospective registries of
gestational drug exposure.
This chapter has been accepted for publication (in press):
Etwel F, Koren G. Bias against the Null Hypothesis in Retrospective Registries of
Gestational Drug Exposure. J Obstet Gynaecol Can. 2016.
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4.1. Introduction.
Typically, medications for use in humans are introduced to the market
supported by reproductive animal data, which are often not predictive of the risk of
human malformation. Furthermore, in pre-marketing clinical trials, accidental
exposures to a medication during pregnancy are typically very rare [1]. However,
because 50% of all pregnancies are unplanned [2], large numbers of women are
exposed inadvertently to medications in early pregnancy. Moreover, many
pregnant women suffer from conditions that require continued treatment during
pregnancy. When a new drug enters the market, case reports of fetal exposure
begin to emerge, but unless a very highly teratogenic signal and a unique
phenotype are evident (such as was noted with thalidomide or isotretinoin) [3], it
takes years before a prospective cohort study of first trimester fetal exposure
becomes available.
Historically, most information about the risks of drugs in pregnancy has
arisen from findings of spontaneous adverse event reports (case reports). This
mechanism of passive surveillance has been well-described [4] and is
advantageous in the identification of a rare or unusual fetal outcome. A major
limitation of retrospective case series is the lack of denominator data, which
precludes estimation of the size of risk with use of the drug compared to the risk in
the general population.
Retrospective registries of exposure during pregnancy (enrolment in which
follows notification by families or physicians after the pregnancy outcome is
known) are typically established by drug companies as part of the regulatory
process and their contents are often reported in the peer-reviewed literature.
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The main concern regarding the interpretation of findings in these registries
is that families with malformed children exposed to a given drug in pregnancy, or
their physicians, will be more likely to report the malformation to registries than
families with healthy children prenatally exposed to the same drug [5]. However,
there is little information available on the precision of the estimates from such
registries. In 1999, our group documented that the rate of major malformation
associated with the antifungal itraconazole was 13% in the retrospective report
collected by the manufacturer, but was only 3.2% in the prospective report
collected by the same company [5]. Since then, however, the hypothesis that
retrospective registries are biased towards higher rates of malformations has not
been further confirmed.
Because most medications are not teratogenic [6], a potentially false
teratogenic signal may elicit anxiety and may lead women not to treat serious
medical conditions. In at least one class of drugs (the statins), a report of adverse
fetal outcomes based on retrospective surveillance [7] led to high levels of anxiety.
However, the adverse fetal outcomes were later shown in a meta-analysis of
prospective studies not to be associated with exposure to statins [8].
The objective of the present study was to compare the rates of major
congenital malformations reported in retrospective and prospective registries for
the same drug to quantify the potential bias of retrospective reports.
4.2. Methods.
We performed a search of the electronic database PubMed from inception to
December 31 2013 for all available full English texts, using the following search
terms: “retrospective pregnancy registry”, “prospective pregnancy registry”,
“reporting bias”, “drug company”, “drug registry”, and combining them with
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“congenital malformations” or “embryopathy”. In addition, several pregnancy
registry annual reports that were documented by drug companies and received by
the Motherisk program at the Hospital for Sick Children in Toronto were reviewed
for the period 1984 to 2011. Motherisk regularly receives these reports upon their
release.
For this analysis, we included published articles and registry reports that
provided data on rates of major malformations in the offspring of women who
were exposed to the specific drug during the first trimester of pregnancy, derived
from both retrospective and prospective registries for the same drug.
The following information was recorded from the registries for each drug:
the total number of major malformations among live born infants; the number of
stillbirths or terminated pregnancies (the numerator); and the total number of
reported live births, stillbirths, elective pregnancy terminations, and miscarriages
(the denominator).
The reported rates of major malformations in the retrospective and
prospective reports from the same registry for the same drug were compared using
Fisher’s exact test. Odds ratios and 95% confidence intervals were also calculated.
The distribution of malformations in each report was compared to the normal
distribution of birth defects reported in the United States, in order to identify
whether there was a specific pattern of malformations [9].
4.3. Results.
The electronic search identified a total of 1316 published articles. After
removing all animal studies, case reports, controlled observational studies, and
review articles without original data, 122 articles were reviewed in detail. Five
drugs or classes of drug identified in peer-reviewed published articles fulfilled the
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inclusion criteria (itraconazole, fluoxetine, acyclovir, statins, and mefloquine) [5,
10-13]. Three drugs from drug company annual reports also met the inclusion
criteria (quetiapine, quadrivalent human papillomavirus vaccine, and montelukast
sodium). In all cases, the rates of major malformations after exposure to these
drugs were significantly higher in data reported retrospectively than in data
reported prospectively (Table 4). For all drugs studied, estimates of major
congenital malformation rates from retrospective registries were higher than from
prospective registries; the median bias was higher by a factor of 4.18 ± 1.23 (range
2.13 to 5.97). For six of these drugs the breakdown of malformations was available
in the reports, and there was no specific pattern of malformations in any of them
(data not shown). Details of each of the eight drug registries can be found in the
Appendix 3.
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Table 4. Rates of major malformation in the eligible registries.
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Retrospective data

Prospective data

Increased
rate*

P
for
difference

OR
(95% CI)

No. of
cases with
malforma
tion /
total No.
of cases
20/253

Rate (%)
(95% CI)

No. of
cases with
malformat
ion/ total
No. of
cases
6/224

Rate (%)
(95% CI)

2.68
(1.2 to 5.8)

2.95

0.014

3.12
(1.23 to 7.91)

Quadrivalent
human
papillomavirus
vaccine
Montelukast Na

12/261

4.60
(2.6 to 7.9 )

24/1113

2.16
(1.4 to 3.2)

2.13

0.049

2.19
(1.08 to 4.43)

11/66

16.67
(9.5 to
27.6)

8/250

3.20
(1.6 to 6.3)

5.21

<0.001

6.05
(2.32 to
15.75)

Itraconazole

17/166

10.24
(6.5 to
15.9)

5/199

2.51
(1.0 to 5.9)

4.08

0.003

4.43
(1.60 to
12.27)

Fluoxetine

89/426

20.89
(17.3 to
25.0)

23/658

3.50
(2.3 to 5.2)

5.97

<0.001

7.29
(4.52 to
11.75)

Acyclovir

7/31

22.58
(11.2 to
40.4)

5/101

4.95
(2.1 to
11.3)

4.56

0.007

5.60
(1.63 to
19.19)

Statins

13/91

14.29
(8.5 to
23.1)

6/158

3.80
(1.7 to 8.2)

3.76

0.005

4.22
(1.55 to
11.54)

Mefloquine

29/115

25.22
(18.1 to
33.9)

38/717

5.30
(3.9 to 7.2)

4.76

<0.001

6.03
(3.54 to
10.27)

Drug name

Quetiapine

7.91
(5.2 to
11.9)

*Increased rate is equal to the retrospective risk percentage divided by prospective risk
percentage
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4.4. Discussion.
In all available registries with both prospective and retrospective collection
of data for the same drug, we found consistently higher rates of congenital
malformations in the reports based on retrospective data collection. The powerful
impact of reporting the results of a retrospective data collection became evident
when Edison and Muenke claimed (based on case reports) that statins increased
teratogenic risk [7]; this claim supported a category X labelling (“the risks
involved in use of the drug in pregnant women clearly outweigh potential
benefits”) for this class of drugs by the Food and Drug Administration in the
United States. However, an increasing number of prospective controlled cohort
studies and a meta-analysis have failed to show such an association [8].
Retrospective data collection appears therefore to result in reporting bias; this
reporting bias can lead to high levels of anxiety and misperception among women
and their health professionals, leading even to the termination of otherwise wanted
pregnancies [6].
This significant reporting bias of registries with spontaneous retrospective
data collection does not apply to controlled retrospective observational studies,
such as case-control or retrospective cohort studies. Typically, in controlled
retrospective studies the measurement of exposure to drugs is not correlated with
the measurement of outcomes, contrary to drug companies' reports [14].
Because, in all cases, the bias against the null hypothesis in retrospective
registries was evident and consistent, an additional hypothesis may be considered.
In conditions in which the retrospective registry for a particular drug does not show
malformation rates above the expected baseline of 3% to 5%, the drug is unlikely
to be associated with a clinically significant increase in teratogenic risk.
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To begin examining this hypothesis, we considered the effects of
thiopurines, which are widely used in the management of inflammatory bowel
disease and other autoimmune conditions. The first retrospective study of
teratogenic effects associated with this drug class reported 31 exposed cases, with
only one case with malformation, which was attributed to another drug [15]. Hence
the malformation rate associated with thiopurines identified in this retrospective
registry was in the range of the 3-5% baseline risk. Agreeing with this study, two
separate meta-analyses of all prospective thiopurine studies suggested that
maternal exposure to this class of medications was not associated with increased
teratogenic risk [16, 17]. This hypothesis will have to be confirmed by additional
research.
4.5. Conclusion.
Our findings confirm that when data related to malformations associated
with drug use in pregnancy are collected in registries retrospectively, studies based
on these data have a major and consistent bias against the null hypothesis. This
bias must be considered when interpreting the findings of such studies.
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Chapter 5: The fetal safety of cetirizine: An observational cohort study and
meta-analysis.
This chapter has been published previously:
Etwel F, Djokanovic N, Moretti ME, Boskovic R, Martinovic J, Koren G. The fetal
safety of cetirizine: an observational cohort study and meta-analysis. J Obstet
Gynaecol. 2014 Jul;34(5):392-9.
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5.1. Introduction.
Second-generation antihistamines (astemizole, loratadine, cetirizine, and
fexofenadine) provide symptomatic relief of allergic disorders without the adverse
effects of first-generation antihistamines, mostly CNS and anticholinergic effects.
Second-generation antihistamines are preferred particularly by patients with a
higher risk for development of adverse effects, including sedation and impairment
sleep architecture [1, 2].
Cetirizine hydrochloride (Reactine)®, a nonprescription selective, secondgeneration histamine (H1) receptor antagonist, is a major active metabolite of
hydroxyzine (first-generation antihistamines) with anti-allergic, antihistaminic and
anti-inflammatory effects. Cetirizine is the most potent antihistamine available and
more effective than loratadine and other H1 receptor antagonists in inhibiting
histamine induced wheal response (swelling) and flare response (vasodilation) [3].
Due to its high potency, cetirizine may be appropriate for most severe allergy
symptoms that are unresponsive to other antihistamines. It has a rapid onset, a long
duration of activity and low potential for interaction with drugs that are
metabolized by the hepatic cytochrome P450 system [3, 4].
It is estimated that up to 20%-30% of women of childbearing age experience
allergic rhinitis and 4%-7% suffer from asthma during pregnancy, making them
two of the most common groups of medical conditions that complicate pregnancy.
The symptoms may vary from mild (sneezing, itching), which commonly can be
relieved by avoiding the source of allergy, to severe nasal obstruction that may
require pharmacotherapy [5]. Product labels state that medications for allergic
rhinitis should be avoided during pregnancy due to lack of fetal safety data [6] and
because half of all pregnancies are unplanned [7], this may lead to fetal exposure to
antihistamine before a woman knows she is pregnant.
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No teratogenic effects were detected with oral cetirizine doses of 60, 188
and 133 times the maximum clinically studied human dose in mice, rats and
rabbits, respectively [8]. However, the animal studies are not necessarily indicative
of adverse effects during pregnancy at clinically relevant doses and are not always
predictive of human response. There are limited human studies reporting cetirizine
exposure in pregnancy and pregnancy outcomes. A small prospective, comparative
study conducted by Motherisk following 39 mothers exposed to cetirizine (37 in
the first trimester) did not find differences in pregnancy outcomes between the
exposed and comparison groups [9]. The most recent data were from the Berlin
teratogen information service, with 196 women exposed in any trimester (11% in
the first trimester), also not showing increased risk of birth defects or other adverse
outcomes [10]. A recent review from the Food and Drug Administration with the
American College of Allergy, Asthma, Immunology and American College of
Obstetrics and Gynecology stated that cetirizine should be considered mainly for
the second and third semester of pregnancy as a second generation agent for
allergic condition in pregnancy if first generation antihistamine agents are not
tolerable [11]. These statements suggest to patients and health care providers that
the fetal safety of cetirizine is still questioned. Because half of all pregnancies are
unplanned, this type of message may increase anxiety among many exposed
women.
Hence, our study objectives were as follows: the primary objective was to
determine whether cetirizine hydrochloride exposure during the first trimester of
human pregnancy is associated with an increased rate of major birth defects above
the baseline rate of 2-5% in the general population. The secondary objective was to
determine the rates of spontaneous abortions, stillbirths, birth weight and neonatal
complications following cetirizine hydrochloride exposure.
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5.2. Methods.
This study includes an observational cohort study and a meta-analysis of all
available studies to date.
5.2.1. Observational cohort study.
5.2.1.1. Study design.
This was a prospectively collected observational cohort study.
5.2.1.2. Settings.
This study was conducted at the Motherisk Program located at the Hospital
for Sick Children in Toronto. The Motherisk Program is a counseling service that
provides pregnant, breastfeeding women, and health professionals information on
the safety and risks of exposures to prescription and over-the-counter medications,
natural health products, chemicals, radiation, and infectious diseases [12]. Women
who called the Motherisk Program between January 1, 2004 and December 31,
2007 were enrolled.
5.2.1.3. Study participants.
Three groups of women were recruited. The first group included pregnant
women exposed to cetirizine hydrochloride during the first trimester of pregnancy.
The second group included women who called the general Motherisk line about
exposure to non-teratogenic agents (control group). The control group was
matched to the study group (first group) according to maternal age at the time of
conception (± 2 years) and gestational age at the time of first call to Motherisk (± 2
weeks). The third group included pregnant women exposed to cetirizine
hydrochloride during the second and/or third trimester of pregnancy (disease
matched non first trimester exposure).
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5.2.1.4. Inclusion criteria.
1. Women who contacted Motherisk regarding information on the safety or risk of
using cetirizine hydrochloride for the treatment of seasonal allergic rhinitis,
chronic idiopathic urticaria and any other allergy at any stage of pregnancy.
2. Women who contacted Motherisk regarding information on the safety of
vitamins or other non-teratogenic exposures (i.e. Tylenol, etc.) at any stage of their
pregnancy.
5.2.1.5. Exclusion criteria.
1. Women who were exposed to teratogenic agents (e.g. anticonvulsants,
isotretinoin, warfarin).
2. Women with medical conditions that may be associated with birth defects or any
pregnancy complications (e.g. diabetes, alcohol abuse).
5.2.1.6. Data collection.
All women in the study group were recruited when they first contacted the
Motherisk program regarding the safety of cetirizine hydrochloride during
pregnancy. At the time of their first call, the study protocol was explained and oral
informed consent was obtained. At this initial call, we collected demographic data,
general health information, and information on exposure to any drugs used
concomitantly with a special focus on the details about cetirizine exposure (dose,
duration and adverse effects) on a previously developed structural questionnaire.
The women were re-interviewed 6 months or more after delivery to obtain
outcome data using standardized follow-up forms. In addition, the mothers’ prepregnancy weight and weight at the time of delivery were recorded. Subsequent to
the completion of the pregnancy follow-up and in order to confirm medical details
of the babies’ health, it was necessary to obtain the verbal permission of the
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women to send a letter to their children’s health care providers. The letters were
sent to the caller’s physicians (family physicians or pediatricians) for verification
of the information obtained from the mothers. The doctors were asked to complete
questionnaires and the state of general health of the babies as well as major and
minor malformations. The follow-up procedures have been approved by Sick
Children Hospital’s Research Ethics Committee.
5.2.1.7. Statistical analysis.
Outcome end points of interest were compared among those exposed to
cetirizine in the first trimester group and control groups (not exposed to cetirizine
and non-first trimester exposed to cetirizine) with the Student’s t test with
Bonferroni correction, Chi-square or the Fisher’s exact test whenever suitable.
5.2.2. Meta-analysis.
A systematic review and meta-analyses were conducted on all observational
cohort studies published (including the current cohort study) that address the effect
of cetirizine on pregnancy outcomes and cohort studies that had hydroxyzine as an
exposed group. Cetirizine is an active carboxylic acid metabolite of hydroxyzine
(first generation antihistamine) [13]. Combining the extracted cetirizine studies and
hydroxyzine studies in one meta-analysis is therefore biologically plausible and
will increase the sample size to estimate the fetal safety of cetirizine and
hydroxyzine during pregnancy.
5.2.2.1. Search strategy.
A systematic review was performed to retrieve all published articles
involving cetirizine or hydroxyzine exposure during pregnancy. This review
followed the guidelines of the Meta-Analysis of Observational Studies in
Epidemiology (MOOSE) group [14]. Searches were conducted using electronic
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databases for possibly relevant articles that were published in any language up to
December 2012. Included databases were PubMed, SCOPUS, EMBASE and
TOXLINE. The literature was searched using drug names (Cetirizine, Cetirizine
Dihydrochloride, Zyrtec, Reactine, Zirtek, Voltric, Cetirizine AL, Hydroxyzine,
Vistaril, Durrax or Atarax) and drug categories based on pharmacological action
(Histamine H1 Antagonists, H1 Antihistaminic, H1 Receptor Blockaders, NonSedating Histamine H1 Antagonists, Second Generation H1 Antagonists or first
Generation H1 Antagonists).
Subsequently, these terms were combined with various MeSH categories
(including pregnancy, pregnancy complications, abnormalities, embryonic and
fetal development, maternal exposure, teratogens) and keywords (including birth
defect, abnormality, malformation, embryopathy). The reference lists of all
retrieved studies, including reviews, were examined for articles not identified by
the search strategy.
5.2.2.2. Study selection.
Studies were included in the meta-analysis if they met the following criteria:
1- Observational cohort studies, but not case control, or case reports.
2- Studies that reported the incidence of malformation and/or other pregnancy
outcomes in the offspring of women who were or were not exposed to cetirizine
during pregnancy (use of a control or comparison group).
3- Sufficient data to calculate the Odd ratios.
4- Reported data that was not included in a later report by the same group of
investigators (to prevent duplication of overlapping reports).
5- A sample size larger than 10.
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6- Human studies only.
Two authors reviewed the studies to determine whether or not they met
inclusion criteria.
5.2.2.3. Data extraction and analysis.
A data extraction form was used to collect the information from each study.
This information included: first author, year of publication, study design, study
location, years of study and outcome measures. Outcome measures were extracted
for either the cetirizine or hydroxyzine exposed group and the control group and
these measures included the whole group number, live birth number, malformed
cases, spontaneous and therapeutic abortion cases, and prematurity (< 37 weeks
gestation) cases. All the data was arranged in 2x2 tables to calculate the odd ratios.
A random-effects meta-analysis model was used to combine the risk data for
malformation and other pregnancy outcomes by using a statistical program called
Comprehensive Meta-Analysis Version 2.0. Odd rations and 95% confidence
intervals were calculated. Heterogeneity of effects was assessed using the Q
statistic. Three meta-analyses were conducted to assess the risk of major
malformations, one for cetirizine studies, one for hydroxyzine studies, and another
one for combined hydroxyzine and cetirizine studies. Two meta-analyses were
performed for the other pregnancy outcomes (spontaneous abortion and
prematurity).
5.3. Results.
5.3.1. Cetirizine cohort study.
The cohort study included 78 pregnancies exposed to cetirizine during the
first trimester (with or without second or third exposure), 56 pregnancies exposed
to cetirizine during second and/or third trimester (no first trimester exposure), and
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134 pregnancies exposed to non teratogenic drugs. Mean of maternal age of the
three groups were similar (between 32 and 33 years).
In the group exposed to cetirizine during first trimester, there were a total of
73 live births counting three sets of twins, five spontaneous abortions, one
therapeutic abortion, two fetal deaths, and eleven premature births. Two cases with
major malformation were reported in the cetirizine first trimester exposed group:
The first case was a child born with a hip dysplasia and the other case was Down’s
syndrome, detected at 14 weeks and ending in therapeutic abortion at 18-19 weeks.
Two cases with minor malformation were reported in the same group:
periventricular leukomalacia was diagnosed in the same child that was born with a
hip dysplasia, and the second case was a child born with a tongue tie.
In the group exposed to cetirizine during only the second and/or third
trimester, there were 57 live births including one set of twins (all the pregnancies
ended with a live birth), and four premature cases. There were no major
malformations and one minor malformation. The child with the minor
malformation was born with esophageal sphincter, which was not fully formed
until 4-5 months. This defect runs in the paternal family.
In our control group, there were 128 live births including one set of twins,
seven spontaneous abortions, and three premature cases. In this control group,
there were three major malformations and one minor malformation. One of the
major malformations was Trisomy 13 found in one of the spontaneously aborted
fetuses. The other two major malformations were infants born with undescended
testes associated with exstrophy of the bladder and right inguinal hernia. The minor
malformation case was an infant born with an umbilical hernia.
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Two comparisons were made, one between the group exposed to cetirizine
during first trimester and the control group (Table 5.1) and the other between the
group exposed to cetirizine during the first trimester and the exposed group to
cetirizine during second or third trimester (Table 5.2). There was no difference in
the rates of major or minor malformation, live births, spontaneous or therapeutic
abortions, still births, and rates of cesarean or neonatal distress among the groups.
However, there were significant differences between the exposed group to
cetirizine during first trimester and the control group in rates of prematurity (P =
0.001), birth weight (P = 0.01) and gestational age at birth (P = 0.006). These
differences were not detected between the group exposed to cetirizine in the first
trimester and the group exposed to cetirizine during the second or third trimesters.
Moreover, sub analysis revealed that offspring of women with asthma, twins and
smoking cases receiving cetirizine exhibited significantly lower birth weights and
rates of prematurity. After excluding them from the study group, these differences
from the control group disappeared (Table 5.3).
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Table 5.1. Outcomes of pregnancies in fetuses that had first Trimester
cetirizine exposure and control group.
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Outcome
Live birth
Spontaneous
abortion
Therapeutic
abortion
Stillbirth
Major
malformations a
Minor
malformations a
Birth weight, g c
Gestational age c
Prematurity c
Cesarean section c
Neonatal distress c
a

Cetirizine T1 group
73/81
5/81

Control group
128/135
7/135

P
0.27
0.77

1/81

0/135

0.38

2/81
2/76

0/135
3/129b

0.14
1.00

2/76

1/128

0.61

3,317±704
39±2.56
11/73
24/70
9/73

3,547± 532
40±1.59
3/128
22/94
9/128

˂ 0.01
˂ 0.006
˂ 0.001
0.16
0.21

: Of live birth, therapeutic abortion and stillbirth.

b

: Of live birth, therapeutic abortion, stillbirth and one case of spontaneous abortion.

c

:Of live birth.
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Table 5.2. Outcomes of pregnancies in fetuses that had first trimester
cetirizine exposure and in fetus exposed to cetirizine during second and/or
third trimester.
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Outcome

Cetirizine T1 group

Live birth
73/81
Spontaneous
5/81
abortion
Therapeutic abortion 1/81
Stillbirth
2/81
Major
2/76
malformations a
Minor
2/76
malformations a
Birth weight, g b
3,317±704
Gestational age b
39±3
b
Prematurity
11/73
b
Cesarean section
24/70
Neonatal distress b
9/73
a
: Of live birth, therapeutic abortion and stillbirth.

Cetirizine non T1
group
57/57
0/57

0.02
0.08

0/57
0/57
0/57

1.00
0.51
0.51

1/57

1.00

3,462±558
39±2
4/57
16/56
11/57

0.21
0.27
0.18
0.57
0.33

b

: Of live birth.
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P

Table 5.3. Outcomes of pregnancies in fetuses that had first trimester
cetirizine exposure and control group after removing of asthma, twins and
smoking cases.
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Outcome

Cetirizine T1 Group

Control Group

Live Birth

56/64

119/126

0.15

Birth weight, g a

3,449±695

3,560±512

0.24

Gestational age a

39±3

40±1

0.11

Prematurity a

5/56

3/119

0.11

a

: Of live birth
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5.3.2. Meta-analyses.
The electronic search identified 1500 literature titles. After removing all
duplicates and reviewing titles and/or abstracts to exclude the animal studies, noncohort studies, review articles without original data, and articles that addressed
pregnancy outcomes of antihistamines exposure other than cetirizine or
hydroxyzine, twelve articles were reviewed in detail. Ten studies fulfilled the
inclusion criteria for the meta-analysis including the current cohort study. The
other four were excluded because one of them had no healthy control groups [15],
one was a case control study [16], one study focused only on one type of
malformation [17], and one study was published only as an abstract [18] and the
same data were included in a peer reviewed publication [9] (Figure 5.1).
Of the ten studies included in our meta-analyses, four studies included
women on hydroxyzine [19, 20, 21, 22], four studies were on cetirizine [10, 23, 24]
and two studies were on hydroxyzine and cetirizine [9, 25] (Table 5.4). All the
included studies measured the risk of major malformations, whereas five studies
assessed the risk of spontaneous abortion [19, 9, 24, 10, current study], and two
studies also assessed prematurity [10, current study]. The Q-statistic for
heterogeneity of effects was not significant for any of the analyses (P > 0.05).
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Figure 5.1. Diagram for search strategy and study selection for the metaanalyses.
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Relevant references identified from electronic databases,
search performed using cetirizine, hydroxyzine or
antihistamine (and related terms) and combined with all
terms related to pregnancy outcomes (n = 1050).

References excluded after
screening titles and/or abstracts:
duplicate, animal studies, noncohort studies, not include
interested drugs or review articles
(n = 1039).

13 publications reviewed for a detailed (n= )
evaluation. 11 from electronic search
and 2 from reference lists.
4 references excluded: no control
groups, case control study, reported
one kind of malformations or the
same data was included in a high
quality publication.

Current cetirizine
cohort study included.

10 studies included in
the meta-analysis.

4 studies on
hydroxyzine.

4 studies on
cetirizine.
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2 studies on hydroxyzine
and cetirizine.

Table 5.4. Characteristics of the nine studies included in the meta-analyses.
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Study name
(year)

Medication
name

No. of
exposed

No. of
controls

Hydroxyzine

79

36

Hydroxyzine

50

50,232

Pregnancy
outcome
evaluated
Malformed,
SA
Malformed

Erez (1971)
[19]
Heinonen
(1977) [21]
Briggs (1994)
[20]

Schatz (1997)
[25]
Einarson
(1997) [9]
Kallen (2002)
[23]
Diav-Citrin
(2003) [22]
Paulus (2004)
[24]
Weber (2008)
[10]
Current study

Hydroxyzine

828

228,273

Malformed

Hydroxyzine, 76
cetirizine
Hydroxyzine, 92
cetirizine
cetirizine
917

82

Malformed

92

Peer review journal

402,628

Malformed,
SA
Malformed

Hydroxyzine

33

844

Malformed

Peer review journal

cetirizine

123

470

Abstract

cetirizine

177

1,521

Cetirizine

76

129

Malformed,
SA
Malformed,
SA, P
Malformed,
SA, P

SA: Spontaneous Abortion, P: Prematurity

50

Publication type
Peer review journal
Book
Book (personal
communication),
control group
published by Schatz
& Petitti
Guest editorial

Peer review journal

Peer review journal
Peer review journal

5.3.2.1. Meta-analysis of hydroxyzine studies that assessed the risk of major
malformations.
Data from six studies with a total of 1,082 women exposed to hydroxyzine
and 279,480 unexposed controls were included in the meta-analysis. The risk for
congenital malformations in the offspring of women exposed to hydroxyzine was
not higher than those in the controls that were not exposed to hydroxyzine (OR
1.21; 95% CI 0.92-1.59) (Figure 5.2).
5.3.2.2 Meta-analysis of cetirizine studies that assessed the risk of major
malformations.
Six potentially relevant cetirizine studies fulfilled the inclusion criteria for
the meta-analysis, two of which were excluded because they reported two zero
events in the exposed and in the control groups (odd ratio could not be calculated
from these studies) [9, 25]. A total of 1,293 exposed and 404,748 unexposed
controls from the remaining four studies were included in the meta-analysis. The
odds ratio (95% CI) for incidence of abnormalities after exposure to cetirizine was
1.26 (0.93-1.69) (Figure 5.3).
5.3.2.3. Meta-analysis of combined hydroxyzine and cetirizine studies that
assessed the risk of major malformations.
This meta-analysis combined all hydroxyzine and cetirizine studies, with a
total of 2,448 exposed and 684,305 unexposed controls. The odds ratio (95% CI)
for incidence of abnormalities after exposure to hydroxyzine or cetirizine was 1.23
(1.01-1.51), which was marginally significant (Figure 5.4).
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5.3.2.4. Meta-analysis of hydroxyzine and cetirizine studies that assessed the
risk of spontaneous abortion.
Five studies examined the risk of spontaneous abortion for pregnant women
exposed to hydroxyzine or cetirizine, and were included in the meta-analysis (total
of 598 exposed and 2,491 unexposed controls). The odd ratio (95% CI) for
incidence of spontaneous abortion after exposure to hydroxyzine or cetirizine was
1.09 (0.77-1.53). (Figure 5.5).
5.3.2.5 Meta-analysis of cetirizine studies that assessed the risk of
prematurity.
Only two studies reported prematurity in the cetirizine- exposed and control
groups, including the current cohort study and there were no hydroxyzine studies
that examined the risk of prematurity (total of 233 exposed and 1,640 unexposed
controls). The odd ratio (95% CI) for incidence of prematurity after exposure to
cetirizine was 1.47 (0.31-7.01) (Figure 5.6).
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Figure 5.2. Odds ratios and 95% confidence intervals for malformations in
offspring of women using hydroxyzine during pregnancy versus control
groups.
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Test of heterogeneity: P-value = 0.808
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Figure 5.3. Odds ratios and 95% confidence intervals for malformations in
offspring of women using cetirizine during pregnancy versus control groups.
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Test of heterogeneity: P-value = 0.984

56

Figure 5.4. Odds ratios and 95% confidence intervals for malformations in
offspring of women using hydroxyzine or cetirizine during pregnancy versus
control groups.
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Test of heterogeneity: P-value = 0.981
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Figure 5.5. Odds ratios and 95% confidence intervals for spontaneous
abortion for women using hydroxyzine or cetirizine during pregnancy versus
control groups.
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Test of heterogeneity: P-value = 0.886
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Figure 5.6. Odd ratios and 95% confident intervals for prematurity in
offspring of women using cetirizine during pregnancy versus control groups.
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Test of heterogeneity: P-value = 0.050
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5.4. Discussion.
5.4.1. Cetirizine cohort study.
The results of our controlled cohort study suggest that this antihistamine,
when taken during organogenesis, is not associated with an increased risk of major
malformations or spontaneous abortions when compared to non teratogenic
medications taken by healthy pregnant women. Importantly, this association was
also not present when compared to disease- matched women who took cetirizine
after the organogenesis period. These results agree with several other human
studies, that there is no risk above the baseline for major malformations when
cetirizine is taken during pregnancy [9, 10].
There were statistically significant differences between the first trimester
(T1) exposed group and the control group in the rate of twins (P = 0.03) and
maternal asthma (P = 0.0007). These two confounders are strongly associated with
prematurity [26, 27]. The control group was not matched for smoking, and
smoking is also a known cause of prematurity [28]. We analyzed the data after
removing these confounders and examined whether the association between
cetirizine exposure during organogenesis and prematurity is still evident. After
removing all twins, asthma and smoking cases from both groups, the association
between cetirizine and prematurity (P = 0.11), birth weight (P = 0.24), and
gestational age at birth (P = 0.11) disappeared (Table 5.3). Just as important, the
association between prematurity and cetirizine use during the first trimester is not
present when we compared it with a disease –match group. These data highlight
the importance of controlling for confounding by indication in pregnancy outcome
studies.
Our cohort study has limited power to show increased teratogenic risk.
Approximately 200 cases and an equal number of matched comparisons are needed
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to detect (with a power of 80% and a =0.05) a five- fold increased teratogenic risk
above the baseline of 3%. To overcome this hurdle, we increased the sample size
by combining the previous human studies in one meta-analysis and estimated the
major malformations and other pregnancy outcomes.
5.4.2. Meta-analyses.
The meta-analyses suggest that the use of hydroxyzine or cetirizine does not
appear to be associated with a major increased risk for malformations. Although
the meta-analysis combining hydroxyzine and cetirizine studies shows a marginal
association of an increased risk for major malformation (odd ratio 1.31; 95% CI
1.01-1.51), this result may not be clinically significant. In particular, as shown in
our cohort study, there may be confounding by indication, as several studies
suggested an increased risk of malformation in offspring of asthmatic patients.
These results were compatible with a case control study published in 2009
[16] that looked at the association between birth defects and antihistamine use
during early pregnancy. Moreover, a non-interventional observational cohort study
published in 1998 [15] followed women who were exposed to newly marketed
drugs at that time, one of them being cetirizine. The results showed that the
proportion of live infants with a congenital abnormality born to mothers exposed to
newly marketed drugs in the first trimester was similar to the percentage of
congenital anomalies in the general population (no congenital cases reported after
cetirizine exposure).
Furthermore, secondary analyses of other pregnancy outcomes showed no
apparent increased risk for spontaneous abortions , prematurity or after exposure to
cetirizine or hydroxyzine.
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5.5. Conclusion.
In conclusion, based on the current cohort study and meta-analysis,
cetirizine is not associated with an increased risk of major malformations or other
adverse fetal outcomes. The study highlights the importance of control for
confounding by indication, in this case asthma, which may adversely affect
pregnancy outcomes irrespective of cetirizine use.
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6.1. Introduction.
Antihistamines (AHs) are among the most commonly prescribed drugs
during pregnancy, with approximately 15% of pregnant women reporting the use
of over-the-counter or prescribed AHs at some point during their pregnancy,
particularly during the first trimester [1-3]. AHs are classified as either H1 or H2
with reference to the relative selectivity of their targeting receptor. H1-AHs are
used for the treatment of nausea and vomiting during pregnancy (NVP), which
occurs in approximately 85% of pregnancies as well as for the symptomatic relief
of asthma, urticaria, allergy, the common cold, and other relatively minor
conditions [4, 5]. H2-AHs are used to treat indigestion and acid reflux [6]. H1-AH
exposure typically occurs most commonly during the first trimester, while H2-AH
exposure is more common thereafter as NVP tends to present during the first
trimester and resolve in the early second trimester and gastric symptoms usually
appear later in pregnancy [7]. Given the large number of pregnant women exposed
to H1-AHs during the first trimester - a critical time for fetal development - there is
a compelling need to examine any potential risks arising from their use during
pregnancy.
The gold standard of clinical research is the double blind randomized
placebo control trial. Unfortunately, this approach is ethically unacceptable when
studying drug safety in pregnancy due to the possibility of exposing pregnant
mothers and their unborn babies to potentially harmful treatments [8].
Consequently, the most practical approach to quantify the safety and risks of H1AH exposure during the first trimester is to conduct a systematic review and metaanalysis of all available observational cohort and case control studies of exposed
mothers [9]. Previous research on the safety of H1-AH use during pregnancy does
exist in the form of meta-analyses. Unfortunately the information from these
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studies is contradictory, outdated or specific to one type of H1-AH, leaving
questions surrounding the safety of all available H1-AHs.
The first meta-analysis conducted over 20 years ago included all the studies
available at that time and concluded that H1-AHs can safely be used during
pregnancy [10]. However, upon re-analysis of all this data, a second group
produced contradictory results with respect to the cohort studies meta-analysis, in
which they showed an increased risk of major malformation in those exposed to
H1-AHs. The same study demonstrated no increased risk when analyzing case
control studies or the studies that focused only on doxylamine [11]. Other studies
have included meta-analyses on doxylamine when used for treatment of NVP [1214], loratidine, hydroxyzine, and cetirizine [15, 16], each generating reassuring
results. The primary objective of the present study is to determine whether H1AHs, used in the treatment of any condition during the first trimester of pregnancy,
are associated with an increased rate of major malformation. Secondary objectives
include assessing the safety of H1-AHs used specifically for the treatment of NVP
as well as examining the effect of H1-AHs on other pregnancy outcomes, including
spontaneous abortions, prematurity, stillbirth, and low birth weight, following first
trimester exposure.
6.2. Methods.
A systematic review and meta-analyses were conducted on all observational
cohort and case control studies published that addressed the effect of H1-AH on
pregnancy outcomes.
6.2.1. Search strategy.
Following the guidelines of PRISMA [17], a systematic review was
performed to retrieve all published articles involving H1-AH exposure during
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pregnancy. Electronic databases including PubMed and EMBASE were searched
from inception till 10 January 2016 for relevant articles published in any language.
Search strategies are presented in Appendix 5. Subsequently, the reference lists of
all collected studies were reviewed for articles not previously identified by the
search strategy.
6.2.2. Study selection.
Any published human study that met the following criteria was included in
the meta-analyses:
1- Observational cohort or case control studies that clearly confirmed in the
original article the exposure to H1-AH during first trimester and those studies that
had enough data to select the group that had first trimester exposure.
2- Studies that had sufficient data to select only major malformation and/or other
pregnancy outcomes in the offspring of women who were exposed to one or more
types of H1-AH during the first trimester of pregnancy and were compared to a
control group, where the control consisted of women who were not exposed to any
drug throughout their entire pregnancy and/or women who were exposed to drugs
other than specific H1-AHs under study.
3- Studies that provided sufficient data to calculate the odds ratios (ORs) and the
95% confidence intervals (95% CI).
4- Studies with a sample size larger than 10.
5- Studies that focused only on medications used for therapeutic purposes.
6- Updated studies by the same group of investigators on the same type of H1-AHs
were selected to prevent duplication of overlapping reports.
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Two authors (FE and MJR) screened the titles and abstracts of all studies
identified by the electronic search to determine whether or not they met inclusion
criteria to evaluate the full text. Full text of likely studies for eligibility was
reviewed by the two authors (FE and LHF). Disagreements were resolved by a
third author (GK).
6.2.3. Data extraction.
Information from each study was collected with the use of a data extraction
form (Appendix 6). Information collected included the drug name of H1-AH , first
author, year of publication, journal name, study design, study location, year of
study, whether exposure occurred during the first trimester, type of control, and
outcome measures.
Outcome measures were extracted for both the exposed and control groups
and included a number of the following: pregnant women, live births, major
malformations (any structural defect that caused significant medical, surgical, or
cosmetic problems) [18], preterm infants (infants born alive before 37 weeks’
gestation), spontaneous abortions (miscarriage; loss of pregnancy before 20 weeks’
gestation), stillbirths (fetal death after 20 weeks ’ gestation), and low birth weight
infants (live born infants of less than 2,500 g (5 pounds 8 ounces))[19]. The
original studies must have used the same terminology for the outcome measures
and/or its definitions in order to be included. Also, if detailed information about
malformation was reported in the original study, screening of the major
malformation was performed. Authors of included studies were not contacted to
obtain data not reported in their original publication.
All the data were arranged in 2x2 tables to calculate the ORs and 95% CI
and all the outcomes were considered binary outcomes (the adverse outcomes had
72

two possible outcomes: all or nothing). When calculating ratios for spontaneous
abortions, as well as for stillbirth, the denominator was the total number of
pregnancies. For prematurity, low birth weight, and major malformation outcomes,
ratios were calculated using live birth when this information was available.
Stillbirths, elective, therapeutic and/or spontaneous abortions that were diagnosed
as major malformations were all counted as major malformation cases.
6.2.4. Data analysis.
Risk data for malformation and other pregnancy outcomes collected in all
studies was combined with the Comprehensive Meta-Analysis Version 2.0, using a
random-effects model. Both odds ratios and 95% confidence intervals were
calculated for each outcome. Heterogeneity among studies was assessed using the
Q statistic, which was then quantified by I2. A significant Q statistic (P<0.05),
represents a high degree of variance among the studies analyzed. An associated I2
value between 0% to 40% might not be important, while between 30% to 60% may
represent moderate heterogeneity, between 50% to 90% may represent substantial
heterogeneity, and between 75% to 100% considerable heterogeneity [20]. Four
separate meta-analyses were conducted to assess the risk of major malformations:
1) All H1-AH exposed cohort studies.
2) Sensitivity analysis of H1-AH cohort studies excluding studies where the
comparison group may have had some H1-AH exposure other than the drug under
investigation.
3) H1-AHs only used for NVP.
4) All H1-AH case control studies.
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Four separate meta-analyses were performed for all other collected pregnancy
outcomes (prematurity, spontaneous abortion, stillbirth, and low birth weight).
6.2.5. Analysis of potential publication bias.
Funnel plots were generated using the Duval and Tweedie’s trim and fill
method for each meta-analysis where the number of studies included was greater
than 10. Funnel plots were visually inspected in order to assess for publication
bias. The number of unpublished studies (K) that were potentially omitted from the
primary analysis was determined; if evidence of publication bias existed (K>0),
adjusted point estimates (ORs) were calculated based on the number of omitted
studies [21].
6.2.6. Quality assessment.
The Newcastle-Ottawa assessment scale for cohort studies and case control
studies was used to evaluate the quality of included studies in the meta-analyses
[22]. The evaluation focused on the following three categories: the selection
category ranged from 0–4 points, the comparability category ranged from 0–2
points, and the outcome category ranged from 0–3 points (the outcome category
was for cohort studies and for case control studies was called the exposure
category). The scale range was from 0 to 9. For the comparability category,
controlling for maternal age was the most important factor, as studies were given 1
point for this factor and if any other factors such as nicotine consumption, drinking
alcohol, diabetes, hypertension, previous abortions and/or previous malformed
children were controlled for, they received 2 points. For the outcome category for
the cohort studies, the follow up period for major malformation had to be at least 6
months.
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6.3. Results.
An electronic search of all databases identified a total of 1724 manuscripts
(Figure 6.1). After removing all duplicate publications and excluding animal
studies, and studies on drug effectiveness, 342 articles were reviewed in detail. A
total of 37 studies (33 cohort studies [7, 16, 23-52] and 4 case control studies [3,
53-55] fulfilled the inclusion criteria for the meta-analysis (Table 6 for
characteristics of the included studies (Appendix 7)).
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Figure 6.1. Flow chart for study selection for the meta-analyses.
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Electronic databases (n = 1724)

Reference lists (n = 256)

After removing duplicates 1820
references remained for title and/or
abstract screening
References excluded (n =
1478): studies for H1- AHs
therapeutic effectiveness,
laboratory studies, studies
in children, and others

References reviewed for a full text
evaluation for eligibility according to
the inclusion criteria (n = 342)

37 studies included in the metaanalysis (33 cohort study and 4 case
control study)
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References excluded (n
=305): review studies
without original data,
case studies, studies
contains non H1 AH
drugs, studies had data in
another reports, data
can’t be extracted ,
studies on specific kind of
malformation, and
studies on H1 AHs not for
therapeutic use

The average quality score of the included studies was 6.08 (± 1.95 (SD)) out
of 9 according to the Newcastle-Ottawa assessment scale. All the included studies
assessed major malformations or major malformation plus other pregnancy
outcomes, except one cohort study that did not assess major malformations but
rather spontaneous abortions and prematurity [7].
6.3.1. Meta-analysis of cohort studies assessing risk of major malformations.
Data from 32 cohort studies [16, 23-52] with a total of 49,635 women
exposed to H1-AH and 1,302,596 unexposed controls were included in this metaanalysis. The risk of major malformation in the offspring of women exposed to
H1-AHs was not higher than that of the control population (OR 1.07; 95% CI 0.981.16) (Figure 6.2). The Q-statistic for heterogeneity of effects was not significant
(P > 0.05, I2 < 25%) and there was no evidence of publication bias in this analysis
(Figure 6.3).
6.3.2. Sensitivity analysis of the meta-analysis of cohort studies assessing risk
of major malformations.
Four cohort studies were excluded [30, 32, 41, 45], since exposure of the
control group to an H1-AH not under investigation could not be ruled out for these
studies. For example, specific H1-AHs were being studied and compared to a
control group, which may have been exposed to antiemetic drugs that have H1AHs such as doxylamine. The remaining 28 cohort studies [16, 23-29, 31, 33-40,
42-44, 46-52] with a total of 21,427 women exposed to H1-AHs and 449,939
unexposed controls were included in the sensitivity analysis. The risk of major
malformation in the offspring of women exposed to H1-AHs was not higher than
that of the control groups (OR 1.01; 95% CI 0.90-1.12) (Figure 6.4). The Qstatistic for heterogeneity of effects was not significant (P > 0.05, I2 = 0%) and
there was no evidence of publication bias in this analysis.
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6.3.3. Meta-analysis of cohort studies assessing risk of major malformations
for H1-AHs used to treat NVP.
There were 18 cohort studies [23-29, 31, 33-37, 44, 46, 50, 52] that studied
H1-AHs as an antiemetic. A total of 27,243 women who were exposed to H1-AHs
for treatment of NVP and 441,623 unexposed controls were included in this metaanalysis. The risk of major malformation in the offspring of women exposed to
H1-AHs when used for the treatment of NVP was not higher than the control group
(OR 0.95; 95% CI 0.87-1.05) (Figure 6.5). There was no indication of difference in
risk of major malformations in the offspring of women exposed to H1-AHs
compared to control. The Q-statistic for heterogeneity of effects was not significant
(P > 0.05, I2 = 0%) and there was no evidence of publication bias in this analysis.
6.3.4. Meta-analysis for case control studies assessing risk of major
malformations.
Four case control studies [3, 53-55] fulfilled the inclusion criteria; a total of
7,270 women exposed to H1-AHs and 90,336 unexposed controls were included in
the meta-analysis. The risk of major malformation in the offspring of women
exposed to H1-AHs was not higher than that of the control group (OR 1.05; 95%
CI 0.90-1.23) (Figure 6.6). The Q-statistic for heterogeneity of effects was not
significant (P > 0.05, I2 = 0%).
6.3.5. Meta-analysis of cohort studies assessing the risk of prematurity.
Nine cohort studies reported prematurity outcomes [7, 16, 29, 42-44, 47, 51,
52] for a total of 1,799 H1-AHs exposed women and 9,156 unexposed controls.
The odds ratio (95% CI) for the incidence of prematurity after exposure to H1-AHs
was 0.96 (0.76-1.20). The Q-statistic for heterogeneity of effects was not
significant (P > 0.05) with the I2 value was between 25%-50% which indicates low
heterogeneity (Figure 6.7).
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6.3.6. Meta-analysis of cohort studies assessing the risk of spontaneous
abortion.
Thirteen cohort studies reported spontaneous abortion outcomes [7, 16, 23,
27, 39, 40, 42, 47-52] for a total of 2,522 H1-AH exposed women and 7,276
unexposed controls. The odds ratio (95% CI) for the incidence of spontaneous
abortion after exposure to H1-AHs was 1.00 (0.83-1.20) (Figure 6.8). The Qstatistic for heterogeneity of effects was not significant (P > 0.05, I2 = 0%), and
there was no evidence of publication bias in this analysis.
6.3.7. Meta-analysis of cohort studies assessing the risk of stillbirth.
Eight cohort studies reported stillbirth outcomes [7, 16, 23, 39, 40, 43, 48,
50] for a total of 1,571 H1-AH exposed women and 3,328 unexposed controls. The
odds ratio (95% CI) for the incidence of stillbirth after exposure to H1-AHs was
1.23 (0.48-3.18). The Q-statistic for heterogeneity of effects was not significant (P
> 0.05, I2 < 25%) (Figure 6.9).
6.3.8. Meta-analysis of cohort studies assessing the risk of low birth weight.
Three cohort studies reported low birth weight outcomes [43, 50, 52] for a
total of 265 H1-AH exposed women and 384 unexposed controls. The odds ratio
(95% CI) for the incidence of low birth weight after exposure to H1-AHs was 1.20
(0.63-2.29). The Q-statistic for heterogeneity of effects was not significant (P >
0.05, I2 = 0%) (Figure 6.10).
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Figure 6.2. Forest plots of all H1-AHs cohort studies that assessed the risk of
major malformations.
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Total odds ratio (95% CI) = 1.07 (0.98- 1.16)
Test of heterogeneity: Q = 40.35, df = 31 (P = 0.12), I2 = 23.16%
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Figure 6.3. Publication bias using funnel plot for meta-analysis of all H1-AHs
cohort studies that assessed the risk of major malformations.
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Open circles represent the included studies, the open rhombus is the observed measure of effect, and the closed
rhombus is the adjusted measure of effect.
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Figure 6.4. Forest plots of H1-AHs cohort studies excluding the studies that
the comparison group may have some H1-AHs exposure that assessed the risk
of major malformations (sensitivity analysis).
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Total odds ratio (95% CI) = 1.01 (0.90- 1.12)
Test of heterogeneity: Q = 11.19, df = 27 (P = 1.00), I2 = 0.00%
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Figure 6.5. Forest plots of H1-AHs used to treat NVP cohort studies that
assessed the risk of major malformations.
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Total odds ratio (95% CI) = 0.95 (0.87- 1.05)
Test of heterogeneity: Q = 8.42, df = 17 (P = 0.96), I2= 0.00%
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Figure 6.6. Forest plots of H1-AHs case control studies that assessed the risk
of major malformations.
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Total odds ratio (95% CI) = 1.05 (0.90- 1.23)
Test of heterogeneity: Q = 21.01, df = 3 (P = 1.00), I2 = 0.00%

90

Figure 6.7. Forest plots of H1-AHs cohort studies that assessed the risk of
prematurity.
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Total odds ratio (95% CI) = 0.96 (0.76- 1.20)
Test of heterogeneity: Q = 13.64, df = 8 (P = 0.09), I2 = 41.36%
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Figure 6.8. Forest plots of H1-AHs cohort studies that assessed the risk of
spontaneous abortion.
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Total odds ratio (95% CI) = 1.00 (0.83- 1.20)
Test of heterogeneity: Q = 10.93, df = 12 (P = 0.54), I2 = 0.00%
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Figure 6.9. Forest plots of H1-AHs cohort studies that assessed the risk of
stillbirth.
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Total odds ratio (95% CI) = 1.23 (0.48- 3.18)
Test of heterogeneity: Q = 8.05, df = 7 (P = 0.33), I2 = 13.09%
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Figure 6.10. Forest plots of H1-AHs cohort studies that assessed the risk of
low birth weight
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Total odds ratio (95% CI) = 1.20 (0.63- 2.29)
Test of heterogeneity: Q = 1.81, df = 2 (P = 0.41), I2 = 0.00%
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6.4. Discussion.
This study provides a quantitative estimate of the risk of adverse pregnancy
outcomes following first trimester exposure to H1-AHs. The study of H1-AHs in
pregnancy, which includes developing a clear picture of the safety and possible
risks associated with their use, is important given their wide use by pregnant
women. As a consequence of being available both over the counter and as a
prescription medication, intentional and accidental exposures are frequent in the
first and subsequent trimesters. To date, the majority of research on H1-AH
exposure in pregnancy has been reassuring, providing evidence suggesting there is
no increased risk associated with their use. Some conflicting studies, however, do
exist, including several original research studies and one meta-analysis [11]. This
highlights the need for an up-to-date review and analysis of H1-AH safety in
pregnancy that includes all new available research studies as well as those
previously reviewed.
Four different meta-analyses were conducted by us to address the potential
effects of H1-AHs with respect to major malformations. As we collected studies
with two different designs, cohort and case control, meta-analyses were conducted
separately for each type.
The first meta-analysis included all 32 available cohort studies, which met
the study inclusion criteria. The results of this meta-analysis contradict the most
recently published meta-analysis on H1-AH safety based on cohort studies,
published in 2014 by Chin et al. [11]. However, this particular meta-analysis
included only 11 studies compared to our 33, with their most recent study being in
1993 [38] whereas ours being in 2014 [16] The lack of randomized studies on H1AH in pregnancy, similar to lack of randomized studies of virtually all drug classes
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in pregnancy, increases the risk of bias and hence, the need to carefully assess such
potential bias.
Of potential importance, given our inclusion criteria, there were three studies
which were excluded from our analysis but whose results add to the H1-AH safety
profile [56-58]. In these studies H1-AH use was not therapeutic but rather as an
overdose or abuse. The results of these studies that showed no association between
H1-AH use and major malformation are important as the exposure of these
pregnant women was to much higher doses than what would have been
experienced in therapeutic use. These findings further corroborate our hypothesis
that H1-AHs are not teratogenic.
Following our analysis of all 32 cohort studies, we performed sensitivity
analyses, trying to address some potential bias, by excluding those studies where
members of the control group might have been exposed to an H1-AH other than
the drug under investigation. As an example, if meclizine safety was being
assessed and compared to a group of women not exposed to meclizine (but where
they could have been exposed to drugs other than meclizine such as doxylamine),
we could not ascertain that women in the control group were not exposed to a
different H1-AH, unless clearly stated by the authors. While still able to provide us
with some safety information, this was not an ideal control group for our analysis.
The results of our sensitivity analysis were consistent with the original analysis
where no association between H1-AH use and major malformation was found.
We have also carried out a separate analysis looking at studies where H1AHs were used to treat NVP. A total 18 of our 32 cohort studies looked
specifically at H1-AH used for the treatment of NVP. The results showed no
increase in the risk of major malformations in the offspring of women exposed to
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H1-AHs used to treat NVP compared to control. There is ample evidence that NVP
renders protective effects on pregnancy outcome, with mothers who experience
morning sickness having better birth outcomes, including reduced risks of
spontaneous abortion, preterm birth, malformation, and children with higher IQ
[59]. Our analysis for this potential bias by indication ruled out a significant bias.
Four case control studies met the inclusion criteria and were included in this
meta-analysis. Although there were many additional case control studies available
in the literature, they could not be included in our meta-analysis since they each
assessed the risk of only one type of malformation. The results of the case control
study analysis did not show an increase in risk of major malformation following
H1-AHs use. Since, the meta-analyses for cohort studies and case control studies
conducted in this current study cannot rule out an increased risk for specific
congenital anomalies, this limitation should be addressed in future research.
To our knowledge, this is the first meta-analysis addressing pregnancy
outcomes other than major malformations, following exposure to any H1antihisimines. These included the potential effect of H1-AHs on prematurity,
spontaneous abortion, low birth weight and stillbirth.
In looking at prematurity, nine cohort studies were available with outcomes.
Individually all nine studies showed no increase in the risk of prematurity
following H1-AH exposure and therefore, as expected, the combined results of the
meta-analysis also found no increased risk for prematurity.
When evaluating the effects of H1-AH on spontaneous abortion, 13 studies
were available with outcomes and included in the meta-analysis. Individually and
combined, these studies showed no increased risk of spontaneous abortion
following H1-AHs exposure. Importantly, results of the initial analysis
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demonstrated evidence of publication bias that required adjusting the overall
estimate to overcome the presence of bias. After the adjustment, the overall result
did not change, indicating there is no increased risk of spontaneous abortion
associated with H1-AH use. This particular meta-analysis is important because
animal models assessing the safety of H1-AHs during pregnancy have suggested
that they may negatively impact the implantation process [60]. Reassuringly, this
meta-analysis shows no increased risk of spontaneous abortion following
therapeutic use of this medication.
Eight cohort studies assessed stillbirth following H1-AH exposure. The eight
studies both individually and when combined showed no increase in the risk of
stillbirth between exposed and control groups. Since the original studies did not
examine the cause of stillbirth in these groups, we cannot rule out the association
between the H1-AH use and stillbirth outcome.
Three studies assessed low birth weight, not showing increased risk. Low
birth weight is caused either by preterm birth or by stunted growth for gestational
age, or a combination of both. Being small for gestational age can be due to
intrauterine growth restriction secondary to many possible factors [61]. There is a
lack of data in the original studies as for the causes of low birth weight, and more
studies will be needed to draw firm conclusions.
The available studies, none of which is randomized, performed over half a
century should increase one’s vigilance for potential sources of bias. Only about
half of the included studies controlled for maternal age and/or other confounders
such as nicotine and alcohol consumption, previous abortions, diabetes, gravidity
and/or parity [3, 7, 16, 25, 37-40, 43, 44, 46, 48, 50, 52, 54, 55]. However, their
results are not distinctively different from those which controlled for these
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variables. Two included studies measured H1-AHS use during the first trimester as
prescriptions filled, without any assurance that the pregnant women actually took
the medications [33, 42]. Eleven studies were conducted in teratology information
services [16, 38-40, 43, 44-52]. This can potentially introduce a selection bias as
there is evidence demonstrating that pregnant women of low socioeconomic class
do not use such services with the same frequency as women of higher
socioeconomic status and thus the study population may not be generalizable [62].
Data collected from different studies may be subjected to bias as different studies
had different reporting standards and different classifications of the outcome.
However, each included study utilized the same standards for its cases and control
groups, so that the estimated risk in each study may not be affected. There are also
sources of potential bias by indication. NVP has been shown to confer more
favorable pregnancy outcome. As shown above, we have addressed this potential
source of bias by analyzing separately only the studies where AH were given for
morning sickness, and this analysis does not suggest an apparent bias in overall
malformation rates. Similarly, AH are sometimes used for the allergic component
of asthma among women, and here a bias against the null hypothesis may be
created by less favorable pregnancy outcome in asthmatic women [63]. However,
available studies did not specify asthma as a diagnosis and hence this potential
source of bias cannot be ruled out.
6.5. Conclusion.
In conclusion, based on our updated meta-analyses, with very large sample
sizes, H1-AHs do not appear to be associated with an increased risk of major
malformation or other adverse fetal outcomes. Despite methodological limitations
and potential sources of unresolved bias, this study may provide important
information to both pregnant women and their health care providers regarding the
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safety of H1-AH use during early pregnancy. At the present time, these metaanalyses cannot rule out an increased risk for specific congenital malformations.
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Chapter 7: When original positive studies of novel therapies are subsequently
nullified; cumulative meta-analyses in preeclampsia.
This chapter has been published previously:
Etwel F, Koren G. When positive studies of novel therapies are subsequently
nullified: cumulative meta-analyses in preeclampsia. Clin Invest Med. 2015 Oct
7;38(5):E274-83.
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7.1. Introduction.
Typically, after laboratory and experimental animal investigations, novel
therapeutic modalities are introduced to humans through case reports and small
non-randomized, prospective studies. These are subsequently followed by
randomized, double blinded, placebo controlled trials (RCTs), which eventually
allow researchers to define whether the modality is sufficiently effective and safe
over an existing gold standard. The lag time between the first published RCT and a
decision by the medical and scientific communities to accept or reject a new
modality, can be relatively long. During this period, scientific communications
through editorials, commentaries, letters to editors and lectures, are vehicles that
may convince clinicians to use or not to use the new treatment.
In the area of maternal-fetal medicine, new therapeutic options are few and
far between [1]. The ethical challenge of exposing a developing fetus to drugs can
cause delays and hesitations among clinicians and drug companies alike. Yet, not
treating serious maternal conditions can also adversely affects the unborn child and
puts the pregnant patient at risk of morbidity and mortality[2].
Usually, when clinician-investigators complete an RCT of a novel modality,
they attempt to publish the results in high citation impact journals, as these assure
wide professional and public dissemination, in addition to increased likelihood of
future grant funding and professional promotion [3]. However, in more than a few
cases, the first, high impact factor publications suggesting a significantly favorable
effect had been followed by negative trials.
The objective of the present study was to examine changes over time in the
pooled effect size of RCT published on the protective effects of antioxidants and
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low dose aspirin against preeclampsia, a common and serious obstetric
complication [4], and identify determinants that may affect these changes.
7.2. Methods.
We used two recently published meta-analyses of RCTs examining the
protective effects of antioxidant treatment and those of low dose aspirin against
preeclampsia [5-6]. The two selected meta-analyses were subjected to
methodological quality assessment using the AMSTAR method [7]. The
assessment of multiple systematic reviews' (AMSTAR) is a tool containing an 11
point questionnaire with each point having four possible answers. The AMSTAR
quality assessment tool falls into three ranges, High (9-11), Medium (5-8), and
Low (0-4) [8]. The quality assessment was applied to the studies in the original
meta-analyses to ensure that the studies selected were of good quality and their
analyses included appropriate inclusion and exclusion criteria to avoid clinical and
methodological heterogeneity and to control for internal validity.
In both meta-analyses, some papers were “positive” in terms of protective
effect (defined by us as RR below 0.9) (RR of 0.9 suggests a 10% protective effect
which was considered by us a reasonable minimum) and some were negative (RR
equal or above 0.9). The overall result of the antioxidant meta-analysis was “no
protective effect” (negative). In the meta-analysis of low dose aspirin, the overall
result was marginally protective. These two meta-analyses were subjected by us to
cumulative meta-analysis and correlation studies.
7.2.1. Cumulative meta-analysis.
We conducted cumulative meta-analyses of the selected meta-analyses
(without conducting new meta-analyses and adding new studies) to detect a
possible time-dependent effect. The cumulative analysis route displays results
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accumulated over time: that is, the second row presents a summary analysis
comprising the first two studies; the third row presents a summary analysis
comprising the first three studies, and so on through the final row. When the data
are arranged by year of publication this shows the effect measure (relative risk)
that could have been achieved at any point in time with each new study’s arrival;
furthermore, the changes in the final conclusion can be examined over time. For
the cumulative meta-analyses the Comprehensive Meta-Analysis Version 2.0
(Biostat, Engelwood NJ) was used. Heterogeneity among studies was assessed
using the Q statistic and the I-squared test. If the Q statistic (P value) is <0.05, it
represents a high degree of variance among the studies analyzed, and the results
are quantified by I-squared values. I-squared between 25%-50% signifies low
heterogeneity, between 50%-75% moderate heterogeneity, and >75% signifies
high heterogeneity [9]. Publication bias was analyzed using Funnel plots for
detecting the presence of gray literature and assessing its impact on the analysis.
The number of unpublished studies (K) that were possibly absent from our analysis
was determined; if evidence of publication bias occurred (K>0), then adjusted
point estimates (RR) were calculated based on the number of omitted studies (K)
using the Duval and Tweedie’s trim-and-fill method.
7.2.2. Correlation studies.
We correlated the journal’s impact factor, citation number of each paper by
using Google scholar during May 2015 and their sample size, with the RR of the
study’s primary results. In the case of antioxidants, we also correlated the journal’s
impact factor with the quality of the paper, by using the Cochrane Collaboration
method [10]. This method demonstrates which articles satisfied all quality
assessment criteria (no risk of bias) and which articles have not satisfied all quality
assessment criteria. Comparison of continuous variables was conducted by the
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Mann Whitney U test, and correlations between variables were calculated by the
Spearman method.
7.3. Results.
The two meta-analyses included in this review were subjected to quality
assessment, where the total AMSTAR scores were high (where both studies had
maximum scores of 11). This suggests that the studies included in the metaanalysis are not subjected to clinical and methodological heterogeneity that may
affect the validity of the overall results. The conducted cumulative meta-analysis
did not show statistically significant heterogeneity since all the P values of the Q
tests were less than 0.05 and the I-square were less than 50%.
7.3.1. Antioxidant studies.
The first RCT included in the antioxidant meta-analysis was published in
1994 and the most recent one was published in 2011. The sample sizes of the 15
included studies ranged between 60-9969 subjects, the journals’ citation impact
factor ranged between 0.60-54.42, and the number of citations of each paper
between 13- 857 (between 2.17/year and 53.56/year) (Table 7.1).
The median sample size of the positive trials (median 267) was tenfold
smaller than the sample size of the negative trials (median 2120) (P=0.017). There
was a significant positive correlation between study size and RR (rho=0.74; P
=0.0016). There was no significant correlation between RR and citation number
(rho=0.239), or between RR and the journal’s impact factor (rho=0.332). In
contrast, the journal’s impact factor significantly correlated with the number of
citations per year (rho=0.82; P =0.00016). Overall, the impact factor of the journal
did not correlate with the quality of the papers as measured by Biberio- Salle et al
[5] by using the Cochrane Collaboration method. Three studies that fulfilled all
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quality criteria (25, 26, 30), with no risk of bias, had a RR of more than 0.9 (0.97,
1.20 and 1.03), showing no protective effect of antioxidant on pre-eclampsia.
During the first 12 years, in 5 studies, the cumulative meta-analysis revealed
that there was a seeming significant protective effect of antioxidant vs. placebo on
the rates of preeclampsia. This effect gradually diminished and was nullified by
larger studies by 2006 (Figure 7.1). After the analysis of the publication bias using
the funnel plot, the analysis detected five missing studies (Figure 7.5) and after
incorporating the studies in the analysis the overall results shows more non
protective effect of the antioxidant (RR=0.91 in the original meta-analysis, vs.
RR= 1.01 adjusted meta-analysis) (Table 7.3).
7.3.2. Low dose aspirin studies.
The first RCT included in the low dose aspirin meta-analysis was published
in 1986 and the most recent one was published in 2012. The sample sizes of the 14
included studies ranged between 44 and 8257 subjects, the journals’ citation
impact factor ranged between 1.41 -54.42, and the number of citations of each
paper was between 9-482 (0.43/year-16.62/year) (Table 7.2).
The median sample size of the positive trials measuring IUGR (median 72)
was 15 fold smaller than the sample size of the negative trials (median 3019)
(P=0.006). Similar trends were seen for preterm delivery and rates of preeclampsia
(Table7.2). There was a trend toward significant positive correlation between study
size and RR for IUGR (rho=; P =0.06). There was no correlation between RR and
citation number, or between RR and the journal’s impact factor. In contrast, the
journal’s impact factor significantly correlated with the number of citations per
year (rho=0.55; P =0.05).
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The cumulative meta-analysis revealed that during the first 8-11 years, there
was a significant protective effect of low dose aspirin vs. placebo on the rates of
IUGR, prematurity and preeclampsia. This effect gradually diminished and was
either nullified or remained marginally significant which was caused by larger
studies starting in 2006 (Figures7.2- 7.4). After the analysis of the publication bias
using the funnel plot, the analysis detected five to six missing studies and after
incorporating the studies in the three meta-analyses the overall results showed
marginally more significance. (from RR=0.77 in the original preeclampsia metaanalysis to RR= 0.83 in the adjusted meta-analysis; from RR=0.86 in the original
preterm birth meta-analysis to RR= 0.98 in the adjusted meta-analysis; and from
RR=0.80 in the original IUGR meta-analysis to RR=1.93 in the adjusted metaanalysis) (Table 7.3).
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Table 7.1. Details of the RCTs included in the meta-analysis of antioxidants
for preventing preeclampsia.
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Study Name
Han [20]

Year
1994

Chappell [21]

1999

Sharma [22]

2003

Steyn [23]

2003

Beazley [24]

2005

Poston [25]

2006

Rumbold [26]

2006

Rumiris [27]

2006

Spinnato [28]

2007

Banerjee [29]

2009

Villar [30]

2009

McCance [31]

2010

Roberts [32]

2010

Xu [33]

2010

Vadillo [34]

2011

Sample
size

RR

Journal name (impact factor)

Number of
citation

Citation
per year

100

0.10

Chinese Med J (2.34)

46

2.19

283

0.46

Lancet (39.20)

857

53.56

100

0.48

Int J Gynecol Obstet (1.56)

68

5.67

200

1.00

J Obstet Gynaecol (0.60)

53

4.42

251

0.92

Am J Obstet Gynecol (3.97)

137

13.70

1877

0.97

Lancet (39.20)

57

6.33

2395

1.20

NEJM (54.42)

398

44.22

60

0.24

Hypertens Preg (1.19)

80

8.89

159

0.88

Obstet Gynecol (4.80)

105

13.13

1355

0.99

J Obstet Gynecol Res (0.90)

13

2.17

707

1.03

BJOG (1.56)

113

18.83

2363

0.81

Lancet (39.20)

55

11.00

749

1.07

NEJM (54.40)

201

40.20

9969

1.04

Am J Obstet Gynecol (3.97)

89

17.80

444

0.75

BMJ (16.30)

80

20.00
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Table 7.2. Details of the RCTs included in the meta-analysis of low dose
aspirin for preeclampsia.
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IUGR

Journal name
(impact factor)

Number
of
citations

Citation
per year

RR (sample size)
Study name

Year

Wallenburg [35]

1986

0.07 (44)

0.12 (44)

0.73 (44)

Lancet (39.21)

482

16.62

Benigni [36]

1989

-

0.38 (33)

0.31 (33)

NEJM (54.42)

249

9.58

Schiff [37]

1989

0.13 (65)

0.31 (66)

0.30 (65)

NEJM (54.42)

314

12.08

McParland [38]

1990

0.11 (100)

-

1.08 (100)

Lancet (39.21)

160

6.40

61

2.77

9

0.43

72

3.43

49

2.72

20

1.11

467

27.47

26

1.73

151

11.62

100

8.33

49

16.33

26

8.67

Preeclampsia

Preterm
birth

Vinnika [39]

1993

0.84 (197)

-

0.46 (197)

Caspi [40]

1994

0.19 (47)

0.75 (47)

0.52 (94)

CLASP [41]

1994

0.88 (7974)

0.90 (7974)

0.90 (8257)

Hermida [42]

1997

0.43 (100)

0.20 (100)

0.50 (100)

Gallery [43]

1997

-

0.65(108)

-

MFMU [44]

1998

0.90 (2503)

0.93 (2503)

1.19 (2503)

Grab [45]

2000

1.43 (43)

-

-

Vainio [46]

2002

0.20 (86)

-

0.33 (86)

Yu [47]

2003

0.95(554)

0.90 (554)

0.90 (554)

Villa [48]

2012

0.72(121)

-

0.33 (121)

Ayala [49]

2012

0.94(350)

0.38 (350)

0.49 (350)
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BJOG
(3.86)
Am J Reprod
Immunol
(2.67)
Lancet (39.21)
Hypertension
(7.63)
Hypertension
Pregnancy
(1.41)
NEJM (54.42)
Ultrasound
Obstet Gynnecol
(3.85)
BJOG
(3.86)
Ultrasound
Obstet Gynnecol
(3.85)
BJOG
(3.86)
Chronobiol Int
(2.88)

Table 7.3. Duval and Tweedie's Trim and Fill summary data for analysis of
publication bias in the two meta-analyses.
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Random Effects Model
Studies
Trimmed
Anti-Oxidant
&
Preeclampsia
Low Dose
Aspirin &
Preeclampsia
Low Dose
Aspirin &
Preterm Birth
Low Dose
Aspirin &
IUGR

Observed Values
Adjusted Values

5

Observed Values
Adjusted Values

5

Observed Values
Adjusted Values

5

Observed Values
Adjusted Values

6

Point
Estimate

Lower
Limit

Upper
Limit

Q-Value

0.91

0.80

1.03

23.55

1.01

0.94

1.16

46.05

0.77

0.62

0.95

19.95

0.83

0·64

1.07

35.61

0.86

0.76

0.98

13.37

0·89

0.76

1.05

25.76

0.80

0.65

0.99

19.00

1.93

0.74

1.18

33.97
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Figure 7.1. Cumulative chronological meta-analysis of risk ratio in RCTs
investigating the effectiveness of antioxidants for preeclampsia.
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Figure 7.2. Cumulative chronological meta-analysis of preeclampsia of RCTs
of women at risk of preeclampsia who took either aspirin or placebo.
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Figure 7.3. Cumulative chronological meta-analysis of preterm birth of RCTs
of women at risk of preeclampsia who took either aspirin or placebo.
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Figure 7.4. Cumulative chronological meta-analysis of IUGR sorted by the
year of publication for trials of women at risk of preeclampsia who took either
aspirin or placebo.
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Figure 7.5. Publication bias using funnel plot of preeclampsia prevention by
antioxidant meta-analysis (open circles are the original studies and closed
circles are the added studies during adjustment).
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7.4. Discussion.
Studies published in high impact factor journals are cited significantly more.
Naturally, this leads physicians to encounter them more often and possibly assume
that these studies reflect the right clinical answer. Similar to our findings, a recent
study has shown that the impact factor predicts 59% of the variation in citations of
systematic reviews. However, the distribution of citations was obviously skewed
[11]. Importantly, our study shows that high impact factor journals do not exhibit
higher likelihood of predicting a correct answer, which implies that the higher
citation impact does not translate into more correct clinical impact. The fact that
they are cited substantially more may thus create a reporting bias. For example, the
second published study by Chappel et al. on antioxidants [21] showed a 54 percent
reduction in risk of preeclampsia with antioxidants and exhibited the highest
number of citations to date (n=857), which may impact clinicians’ decision in
considering patient care. Yet, this study did not predict correctly the overall effect
of antioxidants, which is null.
What are the reasons that first studies often declare a dramatic effect only to
be nullified later? Our study offers several plausible explanations:
Firstly, as shown by our results, studies with smaller sample sizes are more
likely to be biased against the null hypothesis and suggest positive results. Small
studies are easier to execute and bring to completion, so naturally they are more
likely to be published first. As major journals are seeking novel discoveries, they
may be more inclined to accept such papers, and hence, to be exposed to the risk of
bias against the null hypothesis.
Secondly, there is a serious and systematic bias against the null hypothesis in
the publication process [12, 13]. We and others have shown that negative studies
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(i.e. those not showing a significant effect) are less likely to be submitted by their
authors [14], less likely to be accepted for scientific presentations or publication by
journals [13, 15], less likely to be quoted by the lay media, [16] and less likely to
be cited in the peer review literature [17]. When these effects are combined, a
serious bias can be produced, potentially creating a spurious positive effect. As
years go by, larger studies are published, and the slow-to-be-accepted negative
papers manage to find their way to PubMed –Medline [18], hence the original
spurious positive effect may be diluted and finally nullified. This is further shown
by the assessment of publication bias, suggesting that there are five to six studies
that have not been published and after incorporating the missing studies the
adjusted overall effect shows further nullification of the signal.
With respect to Impact Factor, it has been and continues to be the leading
journal quality indicator despite recognized weaknesses such as the effects of selfcitation, review articles, the total number of articles published, and English
language bias [3]. Related to the issues addressed in the present study, a recent
evaluation of 13 trauma journals concluded that the impact factor of a journal was
a poor measure of the clinical relevance of its papers. Specifically, the authors
found that high impact journals did not address clinical research in surgery and
when they did, there was a delay before such papers were cited [18].
In the case of preeclampsia, the biological plausibility of either antioxidants
or low dose aspirin in experimental models has led to great therapeutic hopes,
which can probably explain the enthusiasm that accompanied the first positive
studies. With both antioxidants and low dose aspirin, the cumulative chronological
meta-analyses revealed that during the first years, there was a seeming significant
protective effect on the rates of preeclampsia and its complications. With both
modalities, the suggested protective effects gradually disappeared and were either
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nullified or remained marginally significant by larger, later studies. Our study
highlights the importance of the cumulative meta-analysis as a powerful evaluation
tool, which has been used more and more often to decide when additional RCTs
are no longer needed therefore suggesting an effect has been proven beyond
reasonable doubt [19].
The fact that initial papers in high impact journals did not predict better the
clinical utility of antioxidants or low dose aspirin for preeclampsia is consistent
with the finding that there were no consistent differences in quality between high
impact journals vs. papers in less prestigious journals. This highlights one of the
criticisms against the citation impact factor, as it may be informative about the
overall quality of the journal, but not of specific papers [11].
7.5. Conclusion.
In conclusion, initial studies, often published in high citation impact factor
journals, are cited significantly more times, but do not exhibit higher likelihood of
predicting a correct answer. Studies with smaller sample sizes are more likely to be
biased against the null hypothesis and as such, cumulative meta-analysis is an
effective tool to predict potential bias against the null hypothesis.
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Chapter 8: General discussion.
8.1. Discussion of research findings.
Although nonrandomized observational studies are of lower quality than
randomized studies, nonrandomized studies have some advantages, as they are
conducted over a long period of time with the number of participants increasing
cumulatively [1]. The almost total lack of randomized control studies of drug
therapy during pregnancy makes observational studies the main source of evidence
in teratology, where data can be synthesized from multiple large prescription
databases. This has led to a more recent form of cohort publications based on large
numbers of patients and exposures, albeit retrospective in nature. These studies’
strengths lie in their large size, but the problem is that the larger cohort studies will
take many years to accumulate and the rate of association of new drugs used by
pregnant women and abnormalities will still need to be estimated in the meantime.
In contrast, small cohort studies conducted by different countries and research
centers will be published years before the large cohort studies can finish collecting
their data. The meta-analysis of small nonrandomized cohort studies from different
sources, but with the same teratogenic questions, can give us early estimates about
drug use during pregnancy, and one can reassure pregnant women who have taken
the drug before they knew they are pregnant or pregnant women who need to use a
certain drug are acting on reliable information.
The current thesis shows, with sufficient evidence how similar are the
conclusions based on the meta-analysis of small studies and those from very large
cohort studies in estimating teratogenicity [2]. This is obvious, especially with
untreated epilepsy, proton pump inhibitors and H2 blockers being safe, while
valproic acid may cause malformations.
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This study enables researchers, clinicians, drug companies and regulators to
trust the meta-analyses of small underpowered controlled studies in identifying the
signals of new drugs used during pregnancy earlier in the course of marketing.
Retrospective registries can be useful as we estimate, based on the available
data, that there is a 4.5 fold amplification factor in retrospective reports compared
to prospective studies of the same compounds by the same company for risk of
congenital malformations from drug exposure during pregnancy [3]. If the
retrospective registries lead to stable increases in teratogenic signal, this must also
mean that, if the retrospective cohort does not show malformation rates above the
expected baseline of 3-5%, the drug is probably not associated with increased
teratogenic risk.
Meta-analysis of observational studies is an effective tool to answer
unresolved research questions in teratology. Meta-analysis has an advantage that
gives more statistical power as similar results from different studies on the same
research question are combined. Meta-analysis also allows a more truthful
representation of different populations than is delivered by the specific study
estimators.
The use of meta-analysis can generate new hypotheses and insight on drug
safety during pregnancy, such as the case of H1 antihistamine in treatment of NVP.
18 of our 33 cohort studies looked specifically at H1 antihistamine use for the
treatment of NVP and were included in our analysis. The results showed no
association between H1 antihistamine use as an antiemetic and major
malformations, which is consistent with previous studies. Yet, with an odds ratio
(0.95) and lower limit of the confidence interval (0.87) less than one, our results
also may suggest a trend towards a protective effect of antihistamines [4].
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However, several studies have shown that NVP itself has a protective effect
on the unborn baby, with mothers who experience morning sickness having better
birth outcomes including reduced risks of spontaneous abortion, preterm birth,
birth defects, and children with higher IQ [5]. There are two well-accepted theories
of how NVP may play a role in better pregnancy outcomes. The first is that the
presence of NVP in pregnancy may prevent the ingestion of harmful teratogens,
either through lack of appetite or physical sickness, therefore protecting the unborn
fetus [6]. The second theory suggests that NVP is secondary to high hormone
levels associated with viable pregnancies, and therefore the symptoms themselves
are not protective, merely they are a negative side effect. Based on the latter theory
rather than being protective, NVP could then be an indication of a more optimal
pregnancy, which would result in better outcomes [7]. However one particular
negative effect of NVP can be the inability to obtain adequate nutrition as a result
of emesis or lack of desire to eat. Women who are treated for their NVP will not
suffer the consequences of inadequate nutrition. It is therefore reasonable to
assume that those women who suffer from NVP (i.e. have optimal hormone levels
for the best outcomes) and are able to obtain optimal nutrition (because they used
antiemetic treatment), which could explain the protective effects of antihistamines
both reported by us and other studies. However, more research studies, with
carefully planned control groups, are required in order to definitively answer
questions surrounding these possible protective effects previously observed.
This study provides important information to both pregnant women and their
health care providers regarding the safety and risk of H1 antihistamines use during
this sensitive time. Although our conclusions are based on a large number of
studies, many others exist which also address fetal safety after exposure to H1
antihistamines. These particular studies suffer from methodological issues that
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made data extraction for meta-analysis difficult and/or impossible. Much of this is
the result of issues presented when studying the safety of medication in pregnancy.
However,

more

observational

controlled

studies,

with

more

consistent

methodology are necessary in order to best assess the safety and risks associated
with not only H1-AH use in pregnancy, but all medication in general.
Cumulative meta-analysis in drug therapy is an essential tool used in
predicting when the direction of the conclusion starts to change, from effective to
no effect may even cross to negative effect, after introducing more trials. The
problem is that the primary studies that discover the new remedy usually suffer
from limited sample size. These studies are often published in high impact factor
journals and are highly cited causing the medical community to trust their
preliminary results. The cumulative meta-analysis of RCTs published on the
protective effects of antioxidants and low dose aspirin against preeclampsia clearly
shows the potential bias against the null hypothesis [8]. This study should
encourage researchers who perform new trials on drug therapy to conduct
cumulative meta-analysis of all previous trials to give the medical community
more insight of the direction of the overall results.
8.2. Methodological challenges in observational studies included in metaanalyses.
Although many observational control studies so far have addressed fetal
safety after exposure to specific chemicals, they suffer from methodological issues
including lack of important information such that performing meta-analyses is
challenging. Therefore, there is a need for clear guidelines for researchers who
perform observational studies to help other researchers in including them in metaanalyses to increase the sample size and reduce clinical heterogeneity that is often
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present in the exposed groups, control groups (comparison group) and in
pregnancy outcomes measures.
8.2.1. Limitations in the exposed group.
The limitations in the exposed group are that the gestational age and
duration, daily dose and the drug indication are not defined or reported
consistently. In addition, the exposed group should optimally be free of conditions
that are known to cause adverse pregnancy outcomes, except for the disease that is
being treated by the drug under study; however, many studies fail to practice
and/or report such exclusion.
8.2.2. Limitations in the control group.
The comparison (or control) group must be composed of healthy volunteers
who have not been exposed to the specific drug under study and/or the same
pharmacological class of the drug under study. Ideally they must not have been
exposed to chemicals that may cause unwanted fetal effects. In addition, the
control group must be free of any disease that may affect pregnancy outcome. The
control group and the exposed group should optimally be matched for maternal age
and, if possible, for other confounders such as nicotine and alcohol consumption,
diabetes, gravidity, parity, previous abortions and/or malformations in previous
pregnancies.
The above conditions are not followed and/or reported by some studies. In
some studies, a disease matched control group is needed because the control group
has the same disease as the exposed group but does not take medications, the
control group is treated for the condition with another class of drugs, or the control
group takes the medication under study but not during the first trimester of
pregnancy.
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8.2.3. Limitations in the pregnancy outcomes.
Regarding malformation, birth defects should be classified as major or minor
and the pediatrician who follows up on a case should confirm the severity of the
malformation. When reporting the major malformation, it is important that
researchers not just give the number of each kind of malformation because
sometimes one case has more than one kind of malformation and this may cause a
multiple counting of malformations; instead, researchers should also indicate the
number of exposed subjects and how many experienced major malformations.
Because some research studies did not follow these guidelines, this caused
exclusion of the studies from our meta-analysis.
Most of the studies examined the association between prenatal exposure to
drugs and major birth defects and they did not study other adverse pregnancy
outcomes, such as spontaneous abortions, prematurity, stillbirth, infant death,
perinatal death, therapeutic abortions, elective abortion, low birth weight, abnormal
head-circumference and abnormal Apgar score. These outcomes are equally
important to address teratogenic potential.
The reasons behind in utero death may be due to birth defects or due to other
causes reasons; however, these incidents are inconsistently reported. Information
on abortions should clarify if they were spontaneous, therapeutic or elective.
8.2.4. Limitations in general.
All the important raw data, such as pregnancy numbers, live births, the
gestational ages at birth, the number of premature births, rates of spontaneous
abortions and all deaths; should be reported, but some studies did not report all
necessary information. Moreover, often updated studies included old data
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published in the past without referencing it, and this could have caused double
counting or an overlap when performing meta-analysis.
It is evident that in case control studies the cases and controls are selected
based on the presence of congenital anomalies. Sometimes we are missing
important data necessary to conduct meta-analysis.
Case control Studies are retrospective and observational. We first identify
the group that has the health outcome of interest (malformations, which in case
control study are cases). Then we identify a group that did not have the health
outcome of interest (malformations), which in case control study are controls. Then
we determine whether or not the participants from each group had a particular
exposure to H1 antihistamine in the past. Table 8 provides the information needed
to conduct the meta-analysis for the cohort study.
In the case control group, the following information is provided:
1- Number of cases (as defined by the case control study that has the
outcome) which are equal to A+C.
2- Number of controls (as defined by case control study that has no
outcome) which are equal to B+D.
Some case control studies did not provide all the necessary information
needed, such as A or C and B or D. This caused an exclusion of these studies from
meta-analysis that may provide important evidence of the fetal safety/risk of the
drug under study.
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Table 8. Information needed to conduct the meta-analysis for cohort study.
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Malformation cases

Total number

Exposed group

A

A+B

Control group

C

C+D

A: Malformation cases that are exposed to the drug under study.
B: Normal cases that are exposed to the drug under study.
C: Malformation cases that are not exposed to the drug under study.
D: Normal cases that are not exposed to the drug under study.

149

8.2.5 Limitations due to study bias.
Study bias is an error that leads to false positive or negative estimation of the
risk. Bias can have different sources from study design to the process of
publication [9]. There is always a challenge to decrease the sources of bias and
increase the generalizability of the data. But, due to the limited data on drug fetal
safety in the literature and lack of RCTs, observational studies have to be included
in meta-analyses even though they did not always control for potential bias. This is
one of the big limitations of meta-analyses conducted in this field.
Bias by indication is one of these limitations, where the disease itself that is
intended to be treated by the drug under study, may cause or protect from the
unwanted pregnancy outcome. This bias can be overcome by proper study design
by having a disease- matched control and if one has large pool of studies, one can
conduct a sensitivity analysis that includes only observational studies where
confounders were adequately addressed in the study design and analysis.
Maternal fetal research deals with observational studies where the
population is usually pregnant women who voluntarily chose to use the drug under
study or accidently took the drug before they knew that they were pregnant. The
population under study may include women with health insurance, good education
and/or previous unwanted pregnancy outcome, who will seek help from the
medical community regarding drug safety during pregnancy [10]. A selection bias
may then be generated and the data may not be easily generalized. This limitation
must be acknowledged in the original studies by reporting the demographic
characteristics of the included population and proper matching for variables such
as previous adverse pregnancy outcome between the exposed and the control
groups.
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There is always a chance that the meta-analysis missed some studies because
of publication bias, where studies with significant results are more likely to be
published in the literature than studies with results that are not statistically
significant. Generating a funnel plot is a common way to address publication bias
but if the number of included studies is less than ten then this method cannot be
used due to lack of sensitivity [11]. Missing studies are not always due to
publication bias. There are other sources that may lead to missing studies such as
language bias where non-English studies are more likely to be missed, citation bias
where studies with non-significant results are less cited by other papers and more
likely to be missed, and availability bias where studies with keywords that did not
match the search terms are more likely to be missed [12].
These limitations cannot be avoided most of the time since the original data
were collected by different groups of researchers with different criteria. Generating
widely acceptable guidelines for observational studies on specific topics on fetal
drug safety can help limit possible biases and may help achieve more precise
estimates of risk/safety of fetal drug exposure during pregnancy.
8.3. Conclusion.
The following points are the general conclusions of the included studies in
this thesis:
1- Meta-analysis of smaller studies appears to generate correct signal in
estimating human teratogenicity years before large and methodologically superior
cohort studies are published [2].
2- The present study confirms a major and consistent bias against the null
hypothesis in retrospective registry studies which needs to be considered when
interpreting such data. Spontaneous reporting is highly selective toward adverse
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events, as families with normal pregnancy outcomes are less likely to report them
[3].
3- Overall, cetirizine is not associated with a clinically important increase in
risk of major malformations or other adverse fetal outcomes. Confounding of
results due to use of the drug for asthma must be considered [13].
4- Based on our meta-analyses, which include a large number of studies, H1
antihistamines are not associated with an increased risk of major malformation or
other adverse fetal outcomes. This study provides important information to both
pregnant women and their health care providers regarding the safety and risk of H1
antihistamine use during this sensitive time [4].
5- Initial intervention studies, often published in high impact factor journals,
are cited significantly more times but do not exhibit a higher likelihood of
predicting a correct long term answer. As such, cumulative meta-analysis is an
effective tool in predicting potential bias against the null hypothesis and the need
for additional studies [8].
8.4. Area of future research.
In the area of therapeutics in pregnancy, we need to continue to study the
safety and efficacy of drugs specific to this population. Conducting small cohort
studies in different parts of the world and combining them in meta-analyses is an
effective tool for this purpose. Furthermore, conducting cumulative meta-analyses
is important whenever new studies emerge in an effort to continue to examine the
safety and efficacy of therapies in pregnancy, or deciding that sufficient data
already exists.

152

8.5. References.
1) Bluhm R. Some observations on observational research. Perspect Biol Med
2009; 52:252-263.
2) Etwel F, Hutson JR, Madadi P, Gareri J, Koren G. Fetal and perinatal exposure
to drugs and chemicals: novel biomarkers of risk. Annu Rev Pharmacol Toxicol.
2014;54:295-315.
3) Etwel F, Koren G. Bias against the Null Hypothesis in Retrospective Registries
of Gestational Drug Exposure. J Obstet Gynaecol Can. 2016.
4) Etwel F, Faught LH, Rieder MJ, Koren G. The risk of adverse pregnancy
outcome after first trimester exposure to H1 antihistamines: a systematic review
and meta-analysis. Drug Safety 2016.
5) Koren G, Madjunkova S, Maltepe C. The protective effects of nausea and
vomiting of pregnancy against adverse fetal outcome--a systematic review. Reprod
Toxicol. 2014;47:77-80.
6) Profet M. Pregnancy sickness as adaptation: a deterrent to maternal ingestion of
teratogens. In:Barkow JH, Cosmides L, Tooby J, editors. The adapted mind:
evolutionary psychology and the generation of culture. New York: Oxford
University
7) Forbes S. Pregnancy sickness and parent-offspring conflict over thyroid
function. J Theor Biol. 2014 Aug 21;355:61-7.
8) Etwel F, Koren G. When positive studies of novel therapies are subsequently
nullified: cumulative meta-analyses in preeclampsia. Clin Invest Med. 2015 Oct
7;38(5):E274-83.
9) Gerhard T. Bias: considerations for research practice. Am J Health Syst Pharm.
2008 Nov 15;65(22):2159-68.
10) Ornoy A, Mastroiacovo P. More on data from teratogen information systems
(TIS). Teratology. 2000 May;61(5):327-8.
11) Sterne JA, Gavaghan D, Egger M. Publication and related bias in metaanalysis: power of statistical tests and prevalence in the literature. J Clin
Epidemiol.2000 Nov;53(11):1119-29.
12) Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to MetaAnalysis. John Wiley & Sons, Ltd, Chichester, UK 2009.
153

13) Etwel F, Djokanovic N, Moretti ME, Boskovic R, Martinovic J, Koren G. The
fetal safety of cetirizine: an observational cohort study and meta-analysis. J Obstet
Gynaecol. 2014 Jul;34(5):392-9.

154

Appendices
Appendix 1: Copyright approval for previously published work.
1) Copyright policies for Annual Reviews.

155

2) Permission for re-publishing from the journal of Obstetrics and
Gynaecology Canada.
Your manuscript JOGC_2016_146_R1 has been accepted
Editor
Mon 9/12, 1:55 PMFatma Etwel
Dear Ms Etwel:
Your manuscript is scheduled for publication in the December issue of JOGC and may be
considered "in press". You should receive edited versions for approval in the next 10 days.
The manuscript may be cited as in press with JOGC. Once you have approved the pdf version
that the publisher will send you, the manuscript will have an assigned doi for citation.
With kind regards.
Yours sincerely,
Timothy Rowe
Editor-in-Chief, Journal of Obstetrics and Gynaecology Canada
www.jogc.com

156

3) Permission for re-publishing from the journal of Obstetrics and
Gynaecology.
Our Ref: DE/IJOG/P6663
04 March 2016
Dear Fatma Etwel,
Thank you for your correspondence requesting permission to reproduce the following article
published in our journal in your printed thesis and to be posted in your university’s repository.
F. Etwel, N. Djokanovic, M. E. Moretti, R. Boskovic, J. Martinovic & G. Koren (2014) The fetal
safety of cetirizine: An observational cohort study and meta-analysis, Journal of Obstetrics and
Gynaecology, 34:5, 392-399
We will be pleased to grant permission on the sole condition that you acknowledge the original
source of publication and insert a reference to the article on the Journals website:
This is the authors accepted manuscript of an article published as the version of record in
Journal of Obstetrics and Gynaecology 28 Mar 2014 http://www.tandfonline.com/
http://tandfonline.com/doi/full/10.3109/01443615.2014.896887
Please note that this license does not allow you to post our content on any third party websites or
repositories.
Thank you for your interest in our Journal.
Yours sincerely
Debbie East– Permissions & Licence Administrator - Journals. Routledge, Taylor & Francis
Group.

157

4) Permission for re-publishing from the journal Drug Safety.
RE: DRSA-D-16-00222R1 Joshi, Nitin, Springer
Thu 11/3/2016 7:01 PM
To: Fatma Etwel
Hi Fatma
If your thesis won’t be available on a public domain, you can use the accepted version of your
manuscript, but not the final publisher’s version, in your thesis. The final version is the one that
we will publish on our Website. You can use the word document that was finally accepted.
Please let me know if you need more information.
Best Regards
Nitin

158

5) Permission for re-publishing from the journal Clinical and Investigative
Medicine.
March 3, 2016
To Whom it may concern
Fatma Etwel, PhD Candidate in Physiology and Pharmacology at Western University, has asked
for permission to cite the following paper in her PhD thesis dissertation:
Etwel F, Koren G. When positive studies of novel therapies are subsequently nullified:
cumulative meta-analyses in preeclampsia. Clin Invest Med. 2015 Oct 7;38(5):E274-83.
As Editor in Chief of Clinical Investigative Medicine and owner of the copyright, I grant
permission for Fatma Etwel to cite this paper as part of her PhD thesis dissertation.
Sincerely,
Robert Bortolussi
Professor Emeritus Dalhousie University
Editor in Chief, Clinical and Investigative Medicine
"Opportunity is missed by most people, because it is dressed in overalls and looks like work."
Thomas Edison

159

Appendix 2: Detailed characteristics of the included examples for Chapter 3.
1) Benzodiazepines and risk of major malformations:
In 1998 a meta-analysis of benzodiazepine and major congenital
malformation concluded that benzodiazepine were not associated with risk of
major malformation (odds ratio 0.90; 95% confidence interval 0.61 to 1.35). This
meta-analysis combined 7 small cohort studies (n ˂ 335 in each study). The last
published study was in 1997 [1].
In 2007 a Swedish group published a large cohort study from Swedish
Medical Birth Register. The total number of group exposed to benzodiazepine was
1929. The final conclusion was the same as the meta-analysis (odds ratio 1.12;
95% confidence interval 0.91 to 1.36) [2]. An updated meta-analysis published in
2011 combined the old meta-analysis with two other cohort studies including the
large one and the final conclusion did not change (odds ratio 1.07; 95% confidence
interval 0.91 to 1.25) [3].
2) Untreated epilepsy and major malformations:
In 2004 a meta-analysis of the association between untreated epilepsy and
major malformation was published. The conclusion was that the risk for congenital
malformation in the offspring of women with epilepsy who had not used
antiepileptic was not higher than among nonepileptic controls (odds ratio 1.92;
95% confidence interval 0.92 to 4.00). This meta-analysis combined 10 small
cohort studies (n ˂ 99 in each study). The last published study was in 2001 [4].
In 2009 a group from Norway published a large cohort study from The
Medical Birth Register of Norway. The total number of children of women with
untreated epilepsy was 1900. The final conclusion was similar to that of metaanalysis (odds ratio 1.0; 95% confidence interval 0.8 to 1.4) [5].
3) Proton Pump Inhibitors and major malformation:
In 2002 a meta-analysis of proton pump Inhibitors and major malformation
was published with the final conclusion that proton pump Inhibitors are not
associated with increased risk of major malformation (Relative Risk 1.18; 95%
confidence interval 0.72 to 1.94). This meta-analysis combined 5 small cohort
studies (n˂ 276 in each study). The last published study was in 2001 [6]. An
updated meta-analysis published in 2009 combined the old meta-analysis with two
more recent cohort studies (one study in 2005 and the other one in 2008), the new
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meta-analysis gave the same final conclusion (odds ratio 1.12; 95% confidence
interval 0.86 to 1.45) [7].
In 2010 a group from Denmark published a large cohort study using data
from The Medical Birth Register, the Prescription Drug Register, the National
Patient Register, the Center Person Register, and Statistics Denmark. The total
number in the group exposed to proton pump Inhibitors was 3651. The final
conclusion was comparable to the meta-analysis (odds ratio 1.10; 95% confidence
interval 0.91 to 1.34) [8].
4) Histamine 2 (H2) blocker and major malformations:
In 2009 a meta-analysis of H2 blocker and major malformation was
published [9]. This meta-analysis combined four cohort studies, three of them
small, and the fourth, which was the most recent one consisted of a large cohort
study that at that time was published as an abstract in 2008 [10] and the full study
published in 2010 [11]. The big study was removed from the meta-analysis by us
and the remaining three small cohort studies were recombined using
comprehensive meta-analysis version 2 software. The meta-analysis, after
removing the large cohort study showed no association with the malformation
(odds ratio 1.00; 95% confidence interval 0.60 to 1.65) and the most recent study
in the reconstructed meta-analysis was in 2005 (Figure 3).
In 2010 a group from Israel published a large cohort study; using data from
Clalit Health Services in Israel, [11]. The total number of exposed group to H2
blocker was 1148. The final conclusion was the same as the reconstructed metaanalysis (odds ratio 1.14; 95% confidence interval 0.89 to 1.45).
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Figure 3. Forest plot of the incidence of congenital malformations after in
utero exposure to H2 blockers (without the large cohort study).
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Study name (year)

Statistics for each study
Odds Lower
ratio
limit

Upper
limit

Events / Total

p-Value Exposed

3 / 142

Odds ratio and 95% CI
Relative
weight

Control

Magee (1996)

0.60

0.14

2.54

0.48

5 / 143

10.63

Ruigomez (1999)

1.37

0.88

2.13

0.16 31 / 555

64 / 1547

52.26

Garbis (2005)

0.74

0.39

1.38

0.34 13 / 553

44 / 1390

37.12

1.00

0.60

1.65

0.99
0.01

0.1
Favours exposure
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1

10
Favours control

100

Relative
weight

5) Angiotensin converting enzyme inhibitors (ACEI) and major
malformations:
In August 2011 a meta-analysis of ACEI and major malformation was
published, concluding that ACEI exposure was not associated with major
malformation compared to “other” antihypertensive exposed controls (odds ratio
1.41; 95% confidence interval 0.66 to 3.04). This meta-analysis combined 4 small
cohort studies (n ˂ 210 in each study). The last published study was in 2011.
Moreover, there were another two meta-analyses in the same publication, one
examining the association between the ACEI exposed group versus healthy
controls (5 studies) and the other looked for the association between “other”
antihypertensive exposed group versus healthy control (4 studies). The two metaanalyses showed an association between congenital malformation and the use of
ACEI (odds ratio 1.78; 95% confidence interval 1.07 to 2.94), or the use of “other”
antihypertensive (odds ratio 1.45; 95% confidence interval 1.15 to 1.83) was
significant [12].
In September 2011 an American group published a large cohort study from
the California birth certificate data and the Kaiser Permanente Northern California
(RER). The total number of exposed group to ACEI was 704 (more than the total
number of the combined studies in the meta-analysis). The association between
exposure to ACEI and “other” antihypertensive was calculated by us. This was
done by creating 2x2 table and by using the risk in the ACEI exposed group
(58/704) and the risk of “other” antihypertensive exposed as a control (327/4390).
The odd ratio was calculated (odds ratio 1.12; 95% confidence interval 0.83 to
1.49) and the conclusion was ACEI exposed group was not associated with major
malformation compared to “other” antihypertensive exposed controls and this
concurred with the meta-analysis conclusion. Additionally, the large cohort study
measured a positive association between ACEI exposed group versus healthy
control (odds ratio 1.58; 95% confidence interval 1.21 to 2.06) and between
“other” antihypertensive exposed group versus healthy control (odds ratio 1.41;
95% confidence interval 1.26 to 1.58). In conclusion, this large study agreed with
the meta-analysis of small studies that ACEI and “other” antihypertensive had the
same risk estimate [13].
6) Valproic acid and major malformations:
In 2006 a meta-analysis of valproic acid and major congenital malformations
was published, concluding that valproic acid was associated with risk of major
malformation (Relative risk 3.77; 95% confidence interval 2.18 to 6.52). This
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meta-analysis combined 3 small cohort studies (n ˂ 159 in each study). The last
published study was in 1999 [14].
In 2010 the EUROCAT antiepileptic group published a large observational
study. The total number of babies exposed to valproic acid was 180. The
conclusion was similar to that of the meta-analysis, where the use of valproic acid
monotherapy was associated with significantly increased risks for 6 of the 14
malformations under consideration example: spina bifida relative risk = 12.7, 95%
CI (7.7-20.7) [15].
7) Valproic acid and intellectual development:
In 2010 a meta-analysis of valproic acid exposure in pregnancy and
intellectual development was published, showing that valproic acid was associated
with reduced intelligence (full-scale IQ was significantly lower (P = 0.001) in the
valproic acid group when compared to the control group). This meta-analysis
combined 3 small cohort studies (n ˂ 42 in each study). The last published study
was in 2005 [16].
In 2010 a group published a prospective observational study by using data
from 25 epilepsy centers in the United State and the United Kingdom. The total
number of exposed group to valproic acid was 92 (more than the total number of
the combined studies in the meta-analysis). The results showed that children
exposed to valproic acid had an IQ score 9 points lower than the score of those
exposed to lamotrigine (P= 0.009). In this study, the lamotrigine exposed group
was considered as a control group because in this study there was no control group
of unexposed children included. The final conclusion indicates that valproic acid
was associated with reduced intelligence [17].
8) Carbamazepine and intellectual development:
In 2010 a meta-analysis of carbamazepine and intellectual development was
published, concluding that carbamazepine was not associated with reduced overall
intelligence (full-scale IQ was not significantly lower (P= 0.39) in the
carbamazepine group compared with the control group). This meta-analysis
combined 3 small cohort studies (n ˂ 87 in each study). The last published study
was in 2005 [16].
In 2010 a group from the US and UK published a prospective observational
study by using data from 25 epilepsy center in the United State and the United
Kingdom. The total number of the exposed group to carbamazepine was 98 (more
than the biggest study in the meta-analysis). The final conclusion was that children
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exposed to carbamazepine had an IQ score 3 points lower than the score of those
exposed to lamotrigine (P= 0. 0.20), where the P value was calculated by us from
the existing data. In this model the lamotrigine-exposed group was considered as a
control group because in this study there was no control groups of unexposed
children included. The final conclusion agreed with the meta-analysis, that
carbamazepine was not associated with reduced intelligence [17].
9) Maternal varicella-zoster infection and major malformations:
In March 1994 a meta-analysis of fetal risk of congenital varicella
syndrome (CVS) after maternal varicella –zoster virus infection in pregnancy,
combined 5 small observation studies (n < than 50 in each study). They found the
weighted average risk for CVS associated with maternal varicella infection was 2.2
% (95% confidence interval, 0 to 4.6 %; range, 0 to 9.1 %). The last published
study included in was in 1994 [18].
In June 1994 a joint large prospective study in Germany and United
Kingdom was published. Between 1980 and 1993, 1739 pregnant women who had
varicella during the first 36 weeks of gestation were followed up. The calculated
risk of congenital varicella syndrome during the first trimester was 2/472 (0.4%,
95% confidence interval, 0.05 to 1.5 %). The denominator (472) was all pregnancy
infected during 0-12 weeks and continuing past 20 weeks gestation, this number
was more than the total number of the combined studies in the meta-analysis The
conclusion from both meta-analysis study and large prospective study was similar,
where the risk of embryopathy associated with maternal infection with varicellazoster virus after first trimester was < 5% [19].
Quality assessment:
All the selected studies were subjected to methodological quality assessment
using the AMASTR method for meta-analytical studies [20], and the MINORS
tool for the large cohort studies [21]. The 'assessment of multiple systematic
reviews' (AMSTAR) is a tool consisting of an 11 item questionnaire, and each item
has four possible answers. There is no overall scoring system in this method. The
AMSTAR quality assessment tool falls into three ranges, High (9-11), Medium (58), and Low (0-4) [22]. MINORS is a validated methodological index to assess the
quality of non-randomized, observational studies. Two points are given for each
question if the article reports and provides an adequate answer; one point is given
if the article reports on the issue but the answer is inadequate; and no points are
given if the article does not report the answer. The global ideal score is out of 24
for comparative studies with a higher score representing greater quality.
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Appendix 3: Characterization of studies included in the analysis of Chapter 4.
1) Quetiapine:
Data were from the Seroquel pregnancy registry up to July 2010. In the
prospective report, there were six live births with congenital anomaly. The report
had 167 live births, 29 cases of elective termination, 19 cases of miscarriage, and 3
cases of fetal death, all the cases without congenital anomaly. In the retrospective
report, there were 18 live births with congenital anomaly and two cases of elective
termination with congenital anomaly. In the report there were 168 live births, 26
cases of elective termination, 33 cases of miscarriage, and six cases of fetal death,
all the cases without congenital anomaly.
2) Quadrivalent human papillomavirus vaccine:
Data were from the Merck pregnancy registry covering the period from first
approval (June 1, 2006) to May 31, 2009. In the prospective report, there were 23
cases of infants/fetuses with major birth defects (21 live births, one fetal death and
one elective abortion) and one miscarriage with a major malformation. The total
number of live births was 974, the total number of fetal death was 10, the total
number of elective abortions was 65 and the total number of miscarriages was 64.
In the retrospective report, there were 11 cases of infants/fetuses with major birth
defects (8 live births, two fetal deaths, and one elective abortion) and one
miscarriage with major malformation. The total number of live births was 190, the
total number of fetal deaths was six, the total number of elective abortions was 21,
and the total number of miscarriages was 44.
3) Montelukast sodium:
Data were from the Merck pregnancy registry covering the period from first
approval (February 20, 1998) to July31, 2009. In the prospective report, there were
eight cases of infants/fetuses with major birth defects (7 live births, and one
elective abortion). The total number of live births was 245, the total number of
elective abortions was two, and the total number of miscarriages was three, with no
reports of fetal death. In the retrospective report, there were nine cases of
infants/fetuses with major birth defects (9 live births) and two miscarriages with
major malformations. The total number of live births was 56, there were 10
miscarriages, and there were no fetal deaths or elective abortions.
4) Itraconazole:
Data were from pregnancies reported to the international pharmacovigilance
department of the manufacturer (Janssen Pharmaceuticals) [1]. In the prospective
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report, there were five cases of infants/fetuses with major birth defects (5 live
births). The total number of live births was 156, the total number of fetal deaths
was three, the total number of elective abortions was 15, and the total number of
miscarriages was 25. In the retrospective report, there were 17 cases of
infants/fetuses with major birth defects (14 live births and three elective abortions).
The total number of live births was 108, the total number of fetal deaths was one,
the total number of elective abortions was 26, and the total number of miscarriages
was 31.
5) Fluoxetine:
Data included fluoxetine-exposed pregnancies reported to Lilly and its
affiliates before April 1996 [2]. There were 658 first-trimester fluoxetine-exposed
pregnancies with outcome other than miscarriage identified prospectively from
spontaneous reports. There were 23 cases of major malformations reported in the
658 pregnancies. A total of 426 pregnancies were reported retrospectively, with 89
cases of malformations associated with fluoxetine exposure in the first trimester.
6) Acyclovir:
Data were from a published article based on the acyclovir in pregnancy
registry, managed by Wellcome Co., between June 1, 1984 and June 30, 1990 with
reports only from the United States [3]. In the prospective report, the number of
infants with congenital abnormalities was five and the number of infants without
congenital abnormalities was 96. In the retrospective report there were seven
infants with congenital abnormalities and 24 infants without congenital
abnormalities.
7) Statins:
Data were from a published article with reports from Merck and Co. to 31
December 2002 [4]. In the prospective cases, there were six children with
malformations and the denominator was the total live births (154) and total fetal
deaths.4 In the retrospective cases, there were 13 offspring with congenital
abnormalities (8 live births, 4 elective abortions, and one miscarriage). The
denominator was 91, which included the total number of pregnancy outcomes.
8) Mefloquine:
Data were from a published article using the Hoffmann–La Roche global
drug safety database for the time frame 31 January 1986 to 26 October 2010 [5];
only cases with first trimester exposure were included. Among prospective cases
there were 38 infants and fetuses with birth defects. The denominator was 717,
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which included all cases with birth defects (n = 38), normal infants (n = 635),
normal fetuses (n = 4), and other disorders (not birth defects) (n = 40). Among the
retrospective cases the number of infants/fetuses with birth defects after first
trimester mefloquine exposure was 29. The denominator was 115, which included
all birth defect cases (n = 29), normal infants (n = 70), normal fetuses (n = 4) and
other disorders (not birth defects) (n = 12).
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Appendix 5: Search strategies for Chapter 6.
Set
1

2
3

4
5

History
H1 Antagonists, Histamine OR Antagonists, Histamine H1 Receptor OR Antihistaminics,
H1 OR H1 Antihistaminics OR Receptor Blockaders, H1 OR H1 Receptor Blockaders OR
Histamine H1 Blockers OR Histamine H1 Receptor Antagonists OR Histamine H1 Receptor
Blockaders OR Antagonists, Histamine H1 OR Blockaders, Histamine H1 Receptor OR
Antihistamines, Classical OR Classical Antihistamines OR Antihistaminics, Classical OR
Classical Antihistaminics OR First Generation H1 Antagonists OR Antihistamines, Sedating
OR Sedating Antihistamines OR Histamine H1 Antagonists, Non Sedating OR Second
Generation H1 Antagonists OR H1 Antihistamines, Non-Sedating OR H1 Antihistamines,
Non Sedating OR Non-Sedating H1 Antihistamines OR Second Generation Antihistamines
OR Antihistamines, Second Generation OR Third Generation H1 Antagonists OR
Brompheniramine OR Promethazine OR Hydroxyzine OR Tripelennamne OR
Dexchlorpheniramine OR Cyproheptadine OR Chlorpheniramine OR Diphenhydramine OR
Dimenhydinate OR Doxylamine OR Dimetinidene OR Cyclazine OR Meclizine OR
Triprolidine OR Dexchlorpheniramine OR Chloropyramine OR Piperazine Derivatives OR
Clemastino OR Pheniramire OR Mizolastine OR Triflupromazine OR Chlorphenoxamine
OR Buclzine OR Prochorperazine OR Dicyclomine OR Phenothiazine OR Pheniramine OR
Methapyrilene OR Thonzylamine OR Pyrilamine OR Tripelennamine OR Phenyltoloxamine
OR Buclizine Or Chlorothen OR Cetirizine OR Fexofenadine OR Loratidine OR
Levocetrizine OR Desloratidine OR Terfenadine OR Astemizole
limit 1 to humans
Malformation OR Abnormality, Congenital OR Congenital Abnormality OR Deformities
OR Deformity OR Congenital Defects OR Congenital Defect OR Defect, Congenital OR
Defects, Congenital OR Abnormalities, Congenital OR Birth Defects OR Birth Defect OR
Defect, Birth OR Defects, Birth OR embryopathy OR Pregnancy Outcomes OR Outcome,
Pregnancy OR Pregnancy Complication OR Live Birth OR Stillbirth OR Premature Birth
OR Prematurity OR Spontaneous Abortion OR Induced Abortion OR Therapeutic Abortion
OR Miscarriage OR Low Birth Weight
limit 3 to humans
2 AND 4
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Appendix 6: Data extraction form for Chapter 6.
Study Title:
Design:

Drug Name:

First Author:

Year:

 retrospective  prospective cohort case control randomized

Study Location (year):

First Trimester:

Quality Score:

Journal:
Reference #:

Type of Control:

Publication Type:

# of pregnancy

# of live birth

# of major malformation

Total

# of preterm infants

Total

# of spontaneous abortions

Total

# of stillbirths

Total

# of low birth weight infants

Total

Exposed

Control

Exposed

Control

Exposed

Control

Exposed

Control

Exposed

Control

Exposed

Control
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Comments

Appendix 7: Characteristics of the included studies for Chapter117 6.
Table 6. Characteristics of the included studies.
First author
(publication year)

Publication
type (study
design)

H1-AHs drug names

Type of control

Pregnancy
outcomes
measured

Comments

GPRG (1963) [23]

Peer-review
journal (cohort
study)

Collection of H1-AHs

Not exposed to any H1AHs

MM, S, St

For NVP metaanalysis, doxylamine
data was only used

Mellin (1963) [24]

Peer-review
journal (cohort
study)

Meclizine,
dimenhydrinate,
cyclizine

Exposed to H1-AHs
under study before or
after pregnancy

MM

Used for NVP metaanalysis

Bunde (1963) [25]

Peer-review
journal (cohort
study)

Doxylamine

Healthy matched control

MM

Used for NVP metaanalysis

Yerushalmy (1965)
[26]

Peer-review
journal (cohort
study)

Meclizine, cylizine

Not exposed to any H1AHs

MM

Used for NVP metaanalysis

Erez (1971) [27]

Peer-review
journal (cohort
study)

Hydroxyzine

NVP group that took
placebo

MM, S

Used for NVP metaanalysis

Milkovich

Peer-review
journal (cohort
study)

Collection of H1-AHs

NVP group that did took
treatment and NVP free
group

MM

Used for NVP metaanalysis

Kullander (1976)
[29]

Peer-review
journal (cohort
study)

Collection of H1-AHs

Not exposed to any H1AHs

MM, P

Used for NVP metaanalysis

Heinonen (1977)
[30]

Book (cohort
study)

Collection of H1-AHs

Not exposed to H1-AHs
under study

MM

Excluded in the
sensitivity analysis

Newman (1977)
[31]

Peer-review
journal (cohort
study)

Collection of H1-AHs

Not exposed to any H1AHs

MM

Used for NVP metaanalysis

Shapiro (1978)
[32]

Peer-review
journal (cohort
study)

Meclizine

Not exposed to H1-AHs
under study

MM

Excluded in the
sensitivity analysis

Smithells (1978)
[33]

Peer-review
journal (cohort
study)

Doxylamine

Exposed to doxylamine
in the non-first trimester
of pregnancy

MM

Used for NVP metaanalysis

(1976) [28]
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Table 6. Characteristics of the included studies (continue).
Publication
type (study
design)

H1-AHs drug names

Type of control

Pregnancy
outcomes
measured

Comments

Jick (1981) [34]

Peer-review
journal (cohort
study)

Doxylamine

Not exposed to any
H1-AHs

MM

Used for NVP meta-analysis

Fleming (1981)
[35]

Peer-review
journal (cohort
study)

Doxylamine

Not exposed to any
H1-AHs

MM

Used for NVP meta-analysis

Gibson (1981)
[36]

Peer-review
journal (cohort
study)

Doxylamine, dicyclome

Not exposed to any
H1-AHs

MM

Used for NVP meta-analysis

Michaelis 1
(1983) [37]

Peer-review
journal (cohort
study)

Doxylamine

Healthy matched
control

MM

Used for NVP meta-analysis

Michaelis 2
(1983) [37]

Peer-review
journal (cohort
study)

Meclizine

Healthy matched
control

MM

Used for NVP meta-analysis

Seto (1993) [38]

Peer-review
journal (cohort
study)

Brompheniramine

Healthy matched
control

MM

-

Pastuzak (1996)
[39]

Peer-review
journal (cohort
study)

Astemizole

Healthy matched
control

MM, S, St

-

Einarson (1997)
[40]

Peer-review
journal (cohort
study)

Cetirizine, hydroxyzine

Healthy matched
control

MM, S, St

-

Schatz (Michigan
Medical study)
(1997) [41]

Guest editorial
(cohort study)

Collection of H1-AHs

Not exposed to H1AHs under study

MM

Excluded in the sensitivity
analysis

Wilton (1998)
[42]

Peer-review
journal (cohort
study)

Cetirizine, loratidine

Not exposed to any
H1-AHs

MM, P, S

-

Loebstein (1999)
[43]

Peer-review
journal (cohort
study)

Terfenadine

Healthy matched
control

MM, P, St, L

-

Kallen (2002)
[44]

Peer-review
journal (cohort
study)

Collection of H1-AHs that
is used for allergy and
Collection of H1-AHs that
is used for NVP

General population
that is not exposed to
any H1-AHs

MM, P

For the all H1-AHs metaanalysis, data for allergy was
used and for NVP meta-analysis,
data for NVP was used

First author
(publication
year)
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Table 6. Characteristics of the included studies (continue).
Publication type
(study design)

H1-AHs drug
names

Type of control

Pregnancy
outcomes
measured

Comments

Kallen & Mottet
(2003) [45]

Peer-review journal
(cohort study)

Meclizine

General population that is
not exposed to Meclizine

MM

Excluded in the
sensitivity analysis

Bsat (2003) [46]

Peer-review journal
(cohort study)

Promethazine

NVP group that took non
H1-AHs treatment

MM

Used for NVP metaanalysis

Diav-Citrin (2003)
[47]

Peer-review journal
(cohort study)

Collection of H1AHs

Healthy control

MM, P, S

-

Moretti (2003)
[48]

Peer-review journal
(cohort study)

Loratidine

Healthy matched control

MM, S, St

-

Abstract (cohort
study)

Cetirizine,
levocetirizine

Healthy control

MM, S

-

Boskovic (2004)
[50]

Peer-review journal
(cohort study)

Doxylamine

Healthy matched control
(with no NVP)

MM, S, St, L

Used for NVP metaanalysis

Weber (2008) [51]

Peer-review journal
(cohort study)

Cetirizine

Healthy control

MM, P, S

-

Ashkenazi (2013)
[52]

Peer-review journal
(cohort study)

Doxylamine

NVP group that took non
H1-AHs treatment

MM, P, S, L

Used for NVP metaanalysis

Etwel (2014) [16]

Peer-review journal
(cohort study)

Cetirizine

Healthy matched control

MM, P, S, St

For P we used that data
without confounders

Aldridge (2014)
[7]

Peer-review journal
(cohort study)

Collection of H1AHs

Healthy matched control

P, S, St

H2-AHs data was
excluded

Eskenazi (1982)
[53]

Peer-review journal
(case control study)

Doxylamine

Not exposed to
Doxylamine

MM

Minor malformation
was excluded

Czeizel (2005)
[54]

Peer-review journal
(case control study)

Dimenhydrinate

Not exposed to
Dimenhydrinate

MM

-

Gilboa (2009) [55]

Peer-review journal
(case control study)

Collection of H1AHs

Not exposed to any H1AHs

MM

-

Li (2013) [3]

Peer-review journal
(case control study)

Collection of H1AHs

Not exposed to any H1AHs

MM

-

First author
(publication year)

Paulus (2004) [49]

H1-AHs: H1 Antihistamines, MM: Major Malformation, P: Prematurity, S: Spontaneous, St: Stillbirth, L: Low birth weigh

177

Curriculum vitae
Name: Fatma Etwel
Place and Year of Birth: Tripoli, Libya. 1976
Post-Secondary Education and Degrees:
-

Tripoli University Tripoli, Libya 1994-1999 B.Sc. Pharmacy

-

University of Western Ontario, Department of Physiology and
Pharmacology 2005-2007 Masters of Science

-

University of Western Ontario, Department of Physiology and
Pharmacology 2011-2016 Ph.D. Candidate

Honors and Awards:
-

Tripoli University Tripoli, Libya. Dean’s Honors Top Student of Faculty of
Pharmacy 1999

-

Ministry of High Education in Libya Graduate Scholarship 2004-2007

-

Ministry of High Education in Libya Graduate Scholarship 2011-2017

Related Work Experience:
-

Demonstrator and Teaching Assistant. Tripoli University Tripoli, Libya.
Department of Pharmacology and Clinical Pharmacy 2000-2003

-

Lecturer and Teaching Assistant. University of Western Ontario,
Department of Physiology and Pharmacology 2006

-

Assistant Lecturer. Tripoli University Tripoli, Libya. Department of
Pharmacology and Clinical Pharmacy 2007-2010

-

Lecturer and Teaching Assistant. University of Western Ontario,
Department of Physiology and Pharmacology 2012-2016

Publications:
-

Etwel F, ElGadi M (2001) Epidemiology of poisoning: A retrospective
study at Tripoli Medical Center. 5th Aljam Conf fpr Med Sci.

178

-

Etwel F, Rieder MJ, Bend JR, Koren G (2008) A surveillance method for
the early identification of idiosyncratic adverse drug reactions. Drug Saf.
2008;31(2):169-80.

-

Koren G, Elzagallaai A, Etwel F (2011) Safety assessment in pediatric
studies. Handb Exp Pharmacol. 2011;205:169-80.

-

Etwel F, Hutson JR, Madadi P, Gareri J, Koren G. Fetal and perinatal
exposure to drugs and chemicals: novel biomarkers of risk. Annu Rev
Pharmacol Toxicol. 2014;54:295-315.

-

Fujii H, Goel A, Bernard N, Pistelli A, Yates LM, Stephens S, Han JY,
Matsui D, Etwell F, Einarson TR, Koren G, Einarson A. Pregnancy
outcomes following gabapentin use: results of a prospective comparative
cohort study. Neurology. 2013 Apr 23;80(17):1565-70.

-

Etwel F, Djokanovic N, Moretti ME, Boskovic R, Martinovic J, Koren G.
The fetal safety of cetirizine: an observational cohort study and metaanalysis. J Obstet Gynaecol. 2014 Jul;34(5):392-9.

-

Etwel F, Russell E, Rieder MJ, Van Uum SH, Koren G. Hair cortisol as a
biomarker of stress in the 2011 Libyan war. Clin Invest Med. 2014 Dec
1;37(6).

-

Marchenko A, Etwel F, Olutunfese O, Nickel C, Koren G, Nulman I.
Pregnancy outcome following prenatal exposure to triptan medications: a
meta-analysis. Headache. 2015 Apr;55(4):490-501.

-

Kaplan YC, Ozsarfati J, Etwel F, Nickel C, Nulman I, Koren G. Pregnancy
outcomes following first-trimester exposure to topical retinoids: a systematic
review and meta-analysis. Br J Dermatol. 2015 Nov;173(5):1132-41.

-

Terrana N, Koren G, Pivovarov J, Etwel F, Nulman I. Pregnancy Outcomes
Following In Utero Exposure to Second-Generation Antipsychotics: A
Systematic Review and Meta-Analysis. J Clin Psychopharmacol. 2015
Oct;35(5):559-65.

-

Etwel F, Koren G. When positive studies of novel therapies are
subsequently nullified: cumulative meta-analyses in preeclampsia. Clin
Invest Med. 2015 Oct 7;38(5):E274-83.

-

Etwel F, Koren G. Bias against the Null Hypothesis in Retrospective
Registries of Gestational Drug Exposure. J Obstet Gynaecol Can. 2016 (in
press).
179

-

Etwel F, Faught LH, Rieder MJ, Koren G. The risk of adverse pregnancy
outcome after first trimester exposure to H1 antihistamines: a systematic
review and meta-analysis. Drug Safety 2016 (in press).

180

